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ABSTRACT

QUANTITATIVE MASS SPECTROMETRIC INVESTIGATIONS OF PROTEIN
BIOMARKERS: SERUM THYMIDINE KINASE 1 AND HUMAN OSTEOPONTIN

By Morse Faria
A dissertation submitted in partial fulfillment of the requirement for Doctor of Philosophy degree
at Virginia Commonwealth University

Virginia Commonwealth University, 2014

Major Director: H. Thomas Karnes, Ph.D.
Professor, Department of Pharmaceutics

Mass spectrometry is being increasingly used in biomarker research mainly due to its ability to
achieve high selectivity coupled with high sensitivity. This dissertation focuses on quantitative
mass spectrometric investigations of two protein biomarkers i.e. serum thymidine kinase 1 (TK1)
and human osteopontin (hOPN).

A liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method for
measuring the activity of TK1 in serum by monitoring the conversion of a TK1 specific
exogenous substrate, 3’-deoxy-3’-fluorothymidine (FLT), to its mono-phosphorylated form 3’deoxy-3’-fluorothymidine monophosphate (FLT-MP). A method to quantify FLT-MP on LCMS/MS was developed and validated. The method was linear over the range of 2.5-2000 ng/mL
with a mean correlation coefficient of 0.9935. The applicability of the developed method was
demonstrated by measuring TK1 activity in serum from hepatocellular carcinoma (HCC) patients
and age-matched controls.
Another method was developed and validated for quantifying hOPN from plasma using
immunoaffinity isolations coupled with microflow LC-MS/MS. A biologically relevant tryptic
peptide ‘GDSVVYGLR’ was used as a signature peptide. The method was validated over a
range of 25-600 ng/mL. A stable isotope labeled (SIL) peptide GDSVVYGLR* and an extended
SIL peptide TYDGRGDSVV*YGLRSKSKKF’ were evaluated as internal standards (IS) to
account for digestion variability. In the digestion variability studies, the use of extended SIL
peptide as internal standard limited the total variability within ±30% in comparison to ±70%
when the SIL-peptide was used. The applicability of the validated method was demonstrated by
analyzing plasma samples obtained from 10 healthy individuals and 10 breast cancer patients.
In a proof of concept investigation, a SIL-peptide was evaluated as an internal standard to
compensate for immunocapture variability during quantification of hOPN by immunoaffinity
coupled LC-MS/MS. Immunocapture variability was induced by varying the antibody amount
per well. The use of SIL-peptide reduced the immunocapture variability from ±81% to ±37%
immunocapture variability.

In addition, an attempt was made to develop a cell based system to evaluate tobacco products for
cardiovascular risk based on the LC-MS/MS measurement of secreted osteopontin and MMP-3
cleaved osteopontin fragments. However, in our preliminary investigations did not yield
detectable levels of the secreted osteopontin concentrations in the cell culture studies and hence
this study was terminated.

CHAPTER 1

1

1.1

MASS SPECTROMETRY BASED PROTEIN BIOMARKER QUANTIFICATION

INTRODUCTION

Biomarkers are used clinically for diagnosis, patient stratification, and therapy selection and for
determination of a surrogate end point in clinical trials (Fleming, et al. 2012, Goodsaid, et al.
2007, Pletcher, et al. 2011). The pharmaceutical industry is optimistic that increased biomarker
applications will enable faster and more successful drug development (Kola, et al. 2004, Lee, et
al. 2009). However, one of the limitations in the use of biomarkers in clinical settings and in
drug development, has been the lack of good quantitative assays (Drucker, et al. 2013,
Makawita, et al. 2010). Traditionally, immunoassays have been used for targeted quantification
of large molecule biomarkers, but issues with selectivity, robustness and long development time
associated with these assays have led to the search for alternative methods for measurement of
biomarkers. (Hoofnagle, et al. 2009, Makawita, et al. 2010, Pan, et al. 2009, Rauh 2012, Wang,
et al. 2009). Over the last decade, there has been a tremendous increase in the use of mass
spectrometry for targeted quantification of biomarkers in clinical settings (Lee, et al. 2009,
Makawita, et al. 2010, Pan, et al. 2009, Ramanathan, et al. 2011, Rauh 2012, Wang, et al. 2009).
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In this chapter, we will review the current practices for development and validation of protein
biomarkers from biological matrices using mass spectrometry based methods.
1.1.1 Biomarkers – Definition and Classification
Biomarker is a combination of the words ‘biological’ and ‘marker’. Over the last two decades,
many definitions have been attributed to the word biomarker. The official National Institute of
Health (NIH) definition is: ‘a characteristic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention” (Atkinsons, et al. 2001). Biomarkers have further been classified into
three types: prognostic, predictive and surrogate end biomarkers (Strimbu, et al. 2010, Weigel, et
al. 2010). Prognostic biomarkers are used to forecast the natural history of a disease irrespective
of treatment. They are used for diagnosis and patient stratification. Predictive biomarkers are
used to suggest the population which is likely to benefit from a particular treatment. For
example, expression of the estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (Her2/neu) are the three most commonly used prognostic and
predictive biomarkers in breast cancer patients (Strimbu, et al. 2010, Weigel, et al. 2010). Over
expression of ER and/or PR in breast cancer patients is used as a predictive biomarker in therapy
selection since these patients would have a higher likelihood of benefit from endocrine based
therapy such as tamoxifen (Strimbu, et al. 2010, Weigel, et al. 2010). Some biomarkers like
Her2/neu can have both prognostic and predictive value (Strimbu, et al. 2010, Weigel, et al.
2010). Her2/neu overexpression is associated with poor prognosis and is indicative of tumor
relapse and shorter overall survival in breast cancer patients. Her2/neu is the target of the anticancer therapeutic monoclonal antibody trastuzumab (Herceptin), and thus, Her2/neu status can
be used to predict the effectiveness of trastuzumab. Thus, Her2/neu status can also be used for
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selection of therapy. In conclusion, prognostic and predictive biomarkers are used for diagnosis,
patient stratification and therapy selection (Buyse, et al. 2010, Strimbu, et al. 2010, Weigel, et al.
2010)
Surrogate endpoint biomarkers provide early prediction of a clinical endpoint and/or the effect of
treatment on the endpoint. Surrogate endpoint markers are useful when the primary end point is
undesirable (death) or when the number of events is so small that one cannot obtain statistically
significant numbers in a clinical trial. A classic example of a surrogate end point marker is blood
cholesterol concentration (Psaty, et al. 1999). Drugs such as simvastatin can use ‘reduction in
blood cholesterol’ as a surrogate endpoint to approve a clinical trial as the primary endpoint (i.e.
stroke, heart attack or death) is undesirable.
1.1.2 Quantification of Protein Biomarkers
Biological or pathological status of a system can be evaluated by measuring the concentrations of
biomolecules such as lipids, proteins and nucleic acids. These biomolecules are involved in
signaling pathways and thus altered expression or activity of these biomolecules can have an
impact on biological status. Hence, these molecules are extensively used as biomarkers. Proteins
are ultimate functional units for various signaling pathways in cells. Protein levels can be
predicted by quantifying mRNA levels but it has a number of limitations (Dhingra, et al. 2005,
Rogers, et al. 2008). The mRNA levels may not correlate with the protein level due to inefficient
translation or to the degradation of mRNA. Additionally, the proteins may not be functionally
active, because its activity may be regulated by post-translational modifications. Proteins may
also be susceptible to degradation or complexation. Hence, measuring protein concentration or
its activity is preferred (Dhingra, et al. 2005, Rogers, et al. 2008).
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Protein biomarkers can be measured from tissue or blood (plasma/serum). Protein biomarkers
found in plasma/serum are preferred over tissue biomarkers as it is comparatively less invasive to
obtain a blood sample than a biopsy sample of a solid tissue. As a result of ease of availability,
plasma/serum biomarkers can be effectively used for screening the general population for early
disease detection, patient stratification and therapy monitoring.
Quantification of protein biomarkers is traditionally carried out using immunoassays. In
particular, Enzyme Linked Immuno Sorbent Assay (ELISA), has been the standard for protein
quantification from biological fluids (Makawita, et al. 2010). Due to high sensitivity, high
throughput and cost effectiveness, sandwich ELISAs have been the primary choice for protein
quantification. ELISA requires a pair of well characterized antibodies having high specificity for
the protein biomarker. One of the major drawbacks of ELISA has been its long development
time (1-2 years) and the huge development cost (100,000’s-1,000,000’s) (Wang, et al. 2009).
This has resulted in restricting the number of biomarker candidates that can advance from the
biomarker discovery phase to the biomarker validation phase. Immunoassays have additional
intrinsic challenges arising from antibody cross-reactivity, the presence of post-translational
modifications on the analyte protein, interferences from autoantibodies and anti-reagent
antibodies, and the high-dose hook effect (Hoofnagle, et al. 2009). This can lead to variable and
inaccurate measurements, which may result in misleading clinical interpretations and decisions
(Hoofnagle, et al. 2009).
Mass spectrometry, as a quantitative tool, was largely restricted to the evaluation of small
molecules untill the 1990’s. "This was due to the lack of good soft ionization techniques that are
required for large molecule quantification. The development of soft ionization techniques such as
electrospray ionization (ESI) and matrix assisted laser desorption ionization (MALDI) facilitated
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the use of mass spectrometry for analysis of peptides and proteins (Makawita, et al. 2010,
Ramanathan, et al. 2011, Rauh 2012). In the last decade, mass spectrometry based bioanalysis
has played a major role in biomarker discovery and validation. Advancements in mass
spectrometric instrumentation and the better quantification strategies has resulted in a shift of
biomarker analysis from immunoassays to mass spectrometry (Makawita, et al. 2010,
Ramanathan, et al. 2011, Rauh 2012).
Tandem mass spectrometry using the selected reaction monitoring (SRM) mode, has been well
established for quantification of small molecules, primarily, due to its high specificity and
sensitivity (Rauh 2012). In the SRM mode, analyte precursor ions and product ions, obtained
after fragmentation of the precursor ion, are selected based on their mass to charge ratio in the
mass analyzer. The SRM mode’s high specificity is due to the low probability of two molecules
having the same mass to charge ratio and fragmenting under standardized conditions to form
fragments of the same mass to charge ratio. Thus, mass spectrometry based quantification using
the SRM mode provides high selectivity and specificity. In addition, it has the ability to measure
absolute levels of post-translational modifications or protein isoforms. These assays involve
lower costs and development time in comparison to ELISA (Makawita, et al. 2010). In addition,
these assays allow easy multiplexing to measure multiple analytes in a single measurement. The
multiplexing ability provides the possibility of evaluating multiple biomarker lead molecules
during the validation phase, allowing a relief in the bottleneck in biomarker discovery. Another
advantage that mass spectrometry provides is the ease of transferability of methods between
matrices and species in comparison to immunoassays. A comparison of immunoassay and LCMS/MS for peptide and protein quantification is given Table 1-1.

5

Table 1-1: Comparison of immunoassay and LC-MS/MS for peptide and protein
quantification
LC-MS/MS

Immunoassay

Not Required unless method involves

A well characterized pair of

immunoaffinity enrichment

antibodies required for ELISA

Development Time

2 Weeks – 2 Months

Months -2 years

Development Cost

Moderate

High

Specificity

High

Moderate

Dynamic Range

103-105

102

Variability

Low

High

Multiplex Capability

High

Low

Ability to measure PTMs

High

Low

Sensitivity

ng/ml

pg/ml

Throughput Capability

Moderate

High

Antibody Requirement
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1.2

MASS SPECTROMETRIC BASED PROTEIN QUANTIFICATION

Mass spectrometry based protein quantification is normally carried out using a stable isotope
dilution approach (Barr, et al. 1996). Most of the current targeted mass spectrometry based
quantification involves digestion of the analyte protein to yield one or more unique tryptic
peptides commonly referred to as signature peptides. The signature peptide is then used as a
surrogate analyte and quantified using the mass spectrometry platform. This approach of
digesting the protein into peptides prior to its instrumental analysis is referred to as bottom-up
quantification. A stable isotope labeled (SIL) form of the signature peptide/protein may be added
during sample processing for internal standardization. These peptides are commonly referred to
as SIL internal standards (SIL-IS) (Li, et al. 2012, Makawita, et al. 2010, Rauh 2012). SIL-IS
peptides are synthetically obtained by incorporating a stable isotope of

13

C and

15

N on one

selected amino acid of the chosen signature peptide sequence (Li, et al. 2012, Makawita, et al.
2010, Rauh 2012). The resulting SIL-IS will have physicochemical properties similar to the
analyte molecule, thus resulting in similar chromatographic separation, ionization efficiency and
fragmentation pattern. As the isotope label on the SIL-IS peptide results in a difference in its
mass with respect to the signature peptide, these peptides can be differentially detected using
mass spectrometry. The ratio of analyte intensity and internal standard intensity is considered as
the final response. Any variation, due to sample complexity or analytical conditions, affecting
the intensity of the analyte will have a proportional effect on the internal standard, thus ensuring
that the final response ratio remains constant. This response ratio evaluation is the fundamental
principle of isotope dilution quantifications (Zhang, et al. 2014). This protein quantification
strategy that relies on the use of a synthetic stable isotope labeled internal standard peptide that
can mimic the signature peptide produced during proteolysis wherein the final response is
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measured as the response ratio between the signature peptide and SIL-IS peptide, is referred to as
the Absolute Quantification (AQUA) strategy. An AQUA strategy was first illustrated by Gerber
et al. in 2003 wherein the absolute levels of low abundance protein and a phosphorylated protein
were quantified from whole cell lysates after an initial separation using SDS/PAGE (Gerber, et
al. 2003). Since then there have been a number of alternate strategies for absolute quantifications
which are discussed in detailed further in the text under internal standardization.
1.2.1 Selection of Signature Peptides
In bottom-up protein quantification, selection of a signature peptide (s) is a critical part of
method development. Some important characteristics of a signature peptide, as summarized by
van den Broek et al (2013), are as follows: (1) It should be unique and specific to the target
protein (2) It should be formed reproducibility during enzymatic digestion (3) It should be stable
throughout the entire analytical procedure (4) It should be sufficiently resolved from background
interferences during chromatographic separations (5) It should be easily ionized and dissociated
and have sufficient sensitivity during MS/MS analysis. Trypsin is the most commonly used
enzyme to carry out proteolytic digestion due to its selective cleavage on the c-terminus of the
positively charged amino acid residues lysine or arginine (Evnin, et al. 1990, Olsen, et al. 2004).
A number of criteria are used during selection of the signature peptides. Tryptic peptides having
a chain length between 5-25 amino acids are preferred to reduce charge state distribution and
provide adequate retention and MS/MS fragmentation. Tryptic peptides containing amino acid
residues with potential post-translational modification (PTM) sites are usually avoided due to a
potential change in peptide mass that would affect reproducible quantification. However, if the
intended purpose is to quantify a post-translational modification, a tryptic peptide containing the
specific PTM is selected (Gerber, et al. 2003, Kirkpatrick, et al. 2005, Liu, et al. 2013). Tryptic
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peptides containing amino acids susceptible to oxidation such as methionine and tryptophan are
avoided as chemical modifications of these molecules can result in a change in its mass and thus
can affect method reproducibility. Usually tryptic peptides containing cysteine residues are
avoided as they undergo iodoacetamidation (Switzar, et al. 2013). However, methods using
signature peptide containing a cysteine residue have been reported after accounting for any mass
change occurring prior to mass spectrometric detection. (Enjalbert, et al. 2013, Palandra, et al.
2013, Zhang, et al. 2011). Additionally, peptides containing ragged ends or dibasic ends next to
each other (such as in Arg-Arg, Lys-Lys or Arg-Lys) should be avoided as they are known to
result in missed cleavages (Brownridge, et al. 2011a, Lawless, et al. 2012, Switzar, et al. 2013,
Wu, et al. 2011) . This could be due to the inability of trypsin to act as a dipeptidyl peptidase
(Brownridge, et al. 2011a, Lawless, et al. 2012). Various commercially available software and
databases that can perform in-silico digestion, verify uniqueness of the tryptic peptides and
determine mass spectrometric parameters are well summarized by Colangelo et al. and are listed
in Table 1-2 (Colangelo, et al. 2013). After in-silico digestion studies, multiple tryptic peptides
are selected as potential signature peptides and evaluated for digestion reproducibility, ionization
intensity and process stability. Digestion optimizations are carried out with recombinant protein.
Chromatographic and mass spectrometric optimization are done using synthetically obtained
peptides. Chromatographic optimization during signature peptide selection ensure adequate
retention and resolution from matrix components. Mass spectrometric optimizations will involve
selection of the mass transitions that are specific to the analyte along with sufficient signal
response. In the case of the unavailability of a recombinant protein, digestion optimization may
be carried out with biologic samples containing the analyte protein. It is advisable to establish the
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selectivity of the signature peptide in the desired matrix using the optimized LC and mass
spectrometric conditions during method development.
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Table 1-2: List of software used for signature peptide selection
Software Use

Name

Vendor

Basic Local Alignment
National Center for Biotechnology Information
Search Tool (BLAST)
PeptideAtlas

Institute for Systems biology (IBS)

Protein Prospector

University of California, San Francisco

SRMAtlas

IBS

Database
Martens, European Molecular Biology
search

PRIDE
Laboratory
GPMdb

Global Proteome Machine Database

NIST peptide mass Spectral

National Institute of Standards and

libraries

Technology (NIST)

PABST

Seattle Proteome Center

Skyline

MacCoss Lab, University of Washington

MRMPilot

ABSciex

Pinpoint

Thermo Scientific

MRMaid

Bessant, Cranfield University

In-Silico
Digestion and
Signature
Peptide
Enhanced Signature Peptide
Transition

Broad Institue
Predictor (ESP)

Selection
MaRiMba

Seattle Proteome Center
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1.2.2 Internal Standardization
The selection of an internal standard is an important aspect of the method development process
for LC-MS/MS quantification of proteins. Internal standards compensate for variation during
sample processing and instrumental response fluctuations. A number of IS strategies for mass
spectrometry based protein quantification have been proposed, previously and reported in several
review articles (Bronsema, et al. 2012, Brun, et al. 2009, Pailleux, et al. 2012, van den Broek, et
al. 2013a).
1.2.3 SIL-Protein IS
A stable isotope labeled (SIL) form of the analyte protein is the most ideal IS for absolute
quantification of proteins since it will have the same physicohemical behavior throughout the
analytical procedure. SIL-proteins can be obtained by incorporating stable isotope labeled amino
acids into the target protein, or PSAQ (Protein Standard Absolute Quantification) standard (Ong
2002, Picard, et al. 2012). This can be achieved using metabolic labeling by incubating cells in a
medium containing stable isotope labeled amino acids popularly known as Stable isotope
labeling by amino acids in cell culture (SILAC) (Ong 2002). Alternatively, SIL-proteins can also
be made by in vitro protein synthesis in a cell free system (Brun, et al. 2007). If the analyte
protein is small it can be chemically synthesized (Jian, et al. 2013). SIL-protein standards can
compensate for immunoaffinity isolation, enzymatic digestions, pre-analytical treatments and
final LC-MS/MS analysis. Hence, analysis carried out with SIL-proteins will be reproducible and
robust. A major restriction in the use of SIL-proteins as ISs for biomarker quantification is their
commercial unavailability or the high cost of production.
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Alternatively, a structural protein analogue can also be used as an internal standard (Halquist, et
al. 2011a, Li, et al. 2011a). It would compensate partially for any digestion variability, however
its major drawback would be its limited ability to compensate for LC-MS/MS variability.
1.2.4 SIL-peptide IS
A SIL form of the signature peptide (SIL-peptide) is the most commonly used internal standard
during protein quantification. A SIL-peptide IS contains amino acids labeled with the stable
isotopes of 13C or 15N thus resulting in peptide analogues which are physiochemically identical to
the signature peptide but can be easily distinguished due to the mass difference. SIL-peptide ISs
can efficiently compensate for extraction recovery, peptide instability and LC-MS/MS
variability. However, unlike a SIL-protein it does not account for proteolytic digestion variability
or any immunoaffinity based purification processes (Brun, et al. 2009, Li, et al. 2012). The
major advantage of using a SIL-peptide is that these can be synthetized at relatively low cost. In
fact, custom synthesized SIL-peptides can be easily obtained from various commercial sources.
A SIL-peptide IS is usually added before enzymatic digestion as it can account for peptide
stability and extraction recovery. However, if a recombinant form of the biomarker is not
available, protein concentrations are calculated stiochometrically, solely based on the known
molar concentration of the SIL-peptide used, in such instances, the IS is added post digestion to
obtain reproducible peptide quantification (Domanski, et al. 2012, Keshishian, et al. 2007).
1.2.5 Extended SIL-peptide
Variation in digestion efficiency can be accounted for with the use of an extended SIL-peptide
which have cleavable groups flanking either side of side of a SIL-peptide (Barnidge, et al. 2004,
Neubert, et al. 2013, Ocana, et al. 2010). Generally, the cleavable groups consist of three to six
amino acids residues from the original protein sequence at both the N- and C- terminus (Kushnir,
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et al. 2013, Neubert, et al. 2013, Ocana, et al. 2010). The addition of an extended SIL-peptide IS
prior to digestion provides a more cost effective alternative to compensate for variability in
digestion efficiency, extraction recovery, LC-MS/MS analysis and peptide stability.
Beynon et al. developed the QonCAT (Quantification concatemer) approach to produce
recombinant proteins that have multiple SIL signature peptides linked together by using an
synthetically obtained artificial gene (Beynon, et al. 2005). This allows application to a large
group of proteins and is useful for multiplexed methods. However, its ability to compensate for
digestion efficiency may be limited as differences may exist between the QconCAT polypeptide
and the analyte proteins with respect to the accessibility of the proteolytic site and digestion rates
(Brownridge, et al. 2011b).
1.2.6 Sample Preparation
Plasma and serum are highly complex biological fluids. In fact, in serum, 20 of proteins
comprise 99% of total protein content and the concentrations of all proteins demonstrate more
than 12 orders of magnitude (Makawita, et al. 2010). Analysis of direct digests of serum or
plasma would be ideal as it would involve minimal sample preparation. However, matrix effects
and interferences from other highly abundant proteins would adversely affect the limit of
quantification and specificity of these mass spectrometric methods. Thus, sample clean-up prior
to enzymatic digestion is an essential part of protein quantification.
1.2.6.1 Protein Purification
1.2.6.1.1 Non-antibody-based protein purification
For proteins smaller than 15 kDa, various strategies which are not specific for protein
purification can employed. Partial protein precipitation using organic solvents along with
surfactants is used as a simple sample purification technique used for smaller proteins or peptides

14

(Halquist, et al. 2011a, Murao, et al. 2007, Sleczka, et al. 2012, Wu, et al. 2011). Protein
precipitation could have low recovery due to losses as a result co-precipitation, which would be a
drawback. Solid phase extraction (SPE) is another purification technique that is employed solely
or along with other purification techniques for sample clean up wherein the analyte is a smaller
protein or peptide (Barton, et al. 2010, Halquist, et al. 2012, Jian, et al. 2013, Sleczka, et al.
2012, Yang, et al. 2009).
1.2.6.1.2 Abundant Protein Depletion
The plasma proteome is comprised of a number of proteins having a concentration range with
more than 10 orders of magnitude (Anderson, et al. 2002). Albumin is a protein that covers
approximately 50% of the total protein content (Anderson, et al. 2002). In fact, it is estimated
that 99% of the serum’s total protein mass is due to the top 20 most abundant proteins. Several
commercial kits are available which use immunoaffinity depletion to selectively remove serum
albumin, immunoglobulins and other high abundant proteins (Anderson, et al. 2006, Echan, et al.
2005, Keshishian, et al. 2009, Polaskova, et al. 2010). These kits have shown to reduce protein
content by up to 85% (Echan, et al. 2005). The high costs of these kits and recovery issues have
been the major drawback of this approach (Fortin, et al. 2009, Keshishian, et al. 2007).
Abundant protein depletion has been used in a number of biomarker quantification methods
(Fortin, et al. 2009, Kuhn, et al. 2004, Yu, et al. 2012). Recently, Lui et al. showed that
isopropanol with 1.0% trichloroacetic acid was effective in removing 95% of the total albumin
in human plasma samples while retaining 60-100% of the three analyte proteins that were
evaluated. The recovery using this approach was found to be better than commercially available
albumin depletion kits (Liu, et al. 2014).
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1.2.6.1.3 Immuno-capture enrichment
Use of specific antibodies directed toward the analyte protein can be used for isolating the
analyte molecule from a complex biological matrix. These enrichments may be carried out with
single or multiple antibodies depending on the availability of analyte specific antibodies and the
amount of selectivity required. Although this technique requires resources and development time
to produce the necessary antibodies, it provides sufficient purification to achieve quantification
of low abundance proteins from plasma (Berna, et al. 2007, Callipo, et al. 2010, Keshishian, et
al. 2007, Ocana, et al. 2010, Winther, et al. 2009). Low recoveries and a lack of specificity are
some of the issues seen during immune-capture enrichment (Adrait, et al. 2012, Dubois, et al.
2007). Another drawback is that the internal standardization of the immuno-capture step requires
the use of a SIL-protein (Bronsema, et al. 2012, Pailleux, et al. 2012) .
Anderson et al. introduced a Stable Isotope Standards with Capture by Anti-Peptide Antibodies
(SISCAPA) strategy wherein immuno-capture enrichment is directed towards a signature peptide
after digestion using anti-peptide antibodies (Anderson, et al. 2004). This technique allowed
quantification of low abundance proteins from plasma, however required the production of
antibodies specific to the signature peptide. Some methods have employed this type of immunocapture online using specialized columns containing analyte specific antibodies (Berna, et al.
2006, Dufield, et al. 2012, Neubert, et al. 2010).
1.2.6.2 Enzymatic Digestion
Most protein quantitative LC-MS/MS methods involve enzymatic digestion of the proteins to
yield smaller peptides which can be easily quantified by commercially available quantitative
mass spectrometers. Some smaller proteins or polypetides may be analyzed without enzymatic
digestions (Becher, et al. 2006, Chambers, et al. 2013, Dubois, et al. 2007, Wang, et al. 2012a).
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A typical protein digestion procedure involves denaturation, reduction and alkylation followed
by proteolysis. Denaturation is carried out to unfold the protein so that it can be easily accessible
to the proteolytic enzyme. Urea is the most commonly used for denaturation during protein
quantification. Alternatively, denaturation has been achieved using other chaotropic agents such
as guanidine HCl, surfactants such as sodium deoxycholate, organic solvents such as methanol
and heat (95ºC) (Hoofnagle, et al. 2008, Switzar, et al. 2013, Wu, et al. 2011, Yang, et al. 2009,
Yu, et al. 2012). Reduction of the protein is carried out using dithiothreitol to break the disulfide
linkages between cysteine residues. The resulting free thiol groups are then derivatized using an
alkylating agent such as iodoacetamide in order prevent formation of disulfide linkages.
Trypsin is the most commonly used enzyme for protein digestions primarily as tryptic peptides a
c-terminal basic residue that favors ionization. In addition, average tryptic peptides have lengths
suitable for detection on commonly used quantitative mass spectrometers (Zhang, et al. 2014).
However, other enzymes such Lys-C, Arg-C, pepsin, chymotrypsin can be used when a specific
cleavage is required (Cingoz, et al. 2010, Liu, et al. 2011, Lu, et al. 2009, van den Broek, et al.
2007). Sequencing or proteomics grade trypsin is normally used as it has higher digestion
efficiency. Additionally, it is treated to prevent autolysis that can result in unwanted cleavage. To
improve digestion efficiency, different approaches have been illustrated including high
temperature, microwave assisted digestion and use of organic solvents (Berna, et al. 2009, Li, et
al. 2009). The ‘pellet digestion’ method is a simplified method in which the proteins are
precipitated using an organic solevent like acetonitrile to form a pellet and the supernatant
containing interfering molecules such as phospholipids are discarded. This method provides an
easy, efficient way of performing a fast clean-up and has resulted in improved digestion
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efficiency in comparison to direct digestion (Duan, et al. 2009, Ouyang, et al. 2012, Yuan, et al.
2012, Yuan, et al. 2013).

1.2.6.3 Strategies for LC-MS/MS Sample Preparation
A number of reviews have compiled various strategies used for protein quantification using LCMS/MS (Ackermann, et al. 2007, Anderson, et al. 2006, Brun, et al. 2009, Gucinski, et al. ,
Kirkpatrick, et al. 2005, Li, et al. 2012, Makawita, et al. 2010, Rauh 2012, Ruan, et al. 2011, van
den Broek, et al. 2013a, Wang, et al. 2009, Zhang, et al. 2014). Figure 1-1 illustrates a decision
tree to choose an appropriate sample preparation strategy. For smaller proteins simple techniques
such as protein precipitation and solid phase extraction would be the method of choice. Protein
purification methods are chosen depending on the analyte concentration, availability of
purification tools (such as analyte specific antibodies) and the matrix. Depending on the analyte
concentration, protein purification methods are selected. Many methods use a ‘double clean-up’
procedure wherein protein purification method is employed prior to digestion combined with a
peptide purification step after digestion (Ahn, et al. 2009, Kushnir, et al. 2013, Neubert, et al.
2013).
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Figure 1-1: Decision tree for sample preparation for protein quantification using LC-MS/MS
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1.2.7 Mass Spectrometric Instrumentation
1.2.7.1 LC-MS/MS
Mass spectrometry based protein quantification is primarily carried out on a high pressure liquid
chromatography coupled with tandem mass spectrometry (LC-MS/MS) system. A list of recently
published methods is summarized in various reviews (Ackermann, et al. 2007, van den Broek, et
al. 2013a, Whiteaker, et al. 2010, Zhang, et al. 2014). The most widely used mass analyzers for
quantification are triple quadropole (QqQ) and Quadrapole Ion Trap (QTrap using the multiple
reaction monitoring (MRM) mode. In the MRM mode, analyte precursor ions and product ions,
obtained after fragmentation of the precursor ion, are selected based on their mass to charge ratio
in the mass analyzer. The MRM mode’s high specificity is due to the low probability of two
molecules having the same mass to charge ratio and fragmenting under standardized conditions
to form fragments of same mass to charge ratio. The non-scanning nature of the MRM mode
allows increased sensitivity up to two orders of magnitude in comparison to the ‘full scan’
modes. MRM mode analysis can be used for polypetides and smaller proteins which have a mass
less than 15 kda without digesting the protein. Some low molecular weight proteins which have
difficulty fragmenting have been analyzed using Pseudo-MRM i.e. monitoring the parent ion to
parent ion transition using very low collision energy (Ji, et al. 2003, Zhu, et al. 2014). Unlike the
MRM mode that relies on isolations based on parent ion and fragment ion mass to charge ratio,
the pseudo-MRM approach relies on a single isolation, which can result in loss of specificity.
Advances in mass spectroscopic sensitivity have been achieved mainly by increasing ionization
efficiency and reducing losses during transmission from the ion source to the MS detector (Shi,
et al. 2012, van den Broek, et al. 2013a). Enhanced ionization efficiency has been achieved by
using nano and micro flow rates and by using higher ion source temperatures. Ion transmission
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efficiency has been improved by using guides or ion funnels (Shi, et al. 2012, van den Broek, et
al. 2013a).
Improved selectivity has been achieved using orthogonal separation modes such as Field
asymmetric waveform ion mobility spectrometry (FAIMS) and differential mobility
spectrometry (Arnold, et al. 2013, Shi, et al. 2012). These ion mobility differentiation systems
separate gas-phase ions based on their mobility differences in high and low electric fields
primarily occurring due to the differences in size and shape of the ions. This orthogonal
separation allows lowering matrix noise and in turn provides higher selectivity and sensitivity.
Additional fragmentation modes measuring MS3 instead of MS2 fragment ions have been used in
some methods to improve MS selectivity. A three to five fold lower LOQ has been achieved
using the MS3 mode in comparison to the MS2 mode, especially, in cases where the limitation
was due to matrix interference (Jeudy, et al. 2014, Lemoine, et al. 2012, Shi, et al. 2012).
1.2.7.2

Full Scan Liquid Chromatography- High Resolution Mass Spectrometry (LCHRMS)

Time of flight (TOF) and orbitrap mass analyzers are currently used to carry out HRMS
quantification. (Gordon, et al. 1999, Gucinski, et al. , Liu, et al. 2011, Rochat, et al. 2013, Ruan,
et al. 2011). These mass analyzers have high resolving power (greater than 30K Full width at
half maximum (FWHM)) and better than 3 parts per million mass accuracy. The high resolving
power and mass accuracy allows resolution between analyte and background signals and thus
can be used for analysis of intact protein molecules. Quantification is done based on peak areas
using narrow mass windows (less than ± 0.05 Da) for the extracted ion chromatogram. Full scan
LC-HRMS quantification is carried out usually for smaller proteins with molecular weights less
than 15 kda (Zhang, et al. 2014). A typical protein spectrum containing multiple charge states
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each having a distribution of its multiple isotopic peaks is seen in a full HRMS scan. High mass
spectrometric resolution allows reproducible detection of individual peaks. The charge state and
isotopic peak with the highest intensity and least background interference is chosen.
Occasionally multiple peaks may be used to improve reproducibility and signal intensity.
(Zhang, et al. 2014). LC-HRMS simplifies sample processing as one can avoid enzymatic
digestions. A comparison of LC-MS/MS and LC-HRMS platforms for protein quantification was
carried out by Dillen et al. (Dillen, et al. 2012). The study indicated that LC-HRMS had a lower
sensitivity than an LC-MS/MS system but provided higher specificity. LC-HRMS platforms can
also be used to carryout quantitative and qualitative measurement simultaneously, thus providing
the possibility of concurrent identification and quantification (L, et al. 2013, Ramanathan, et al.
2011).
1.2.7.3 Chromatographic System
Liquid chromatography is used for separation of the protein or peptide mixture prior to mass
spectrometric detection. Usually, reversed phase liquid chromatography (RPLC) is used to
achieve separation of the peptide mixture (Ahn, et al. 2009, Barton, et al. 2010, Berna, et al.
2009, Callipo, et al. 2010, Fortin, et al. 2009, Kuhn, et al. 2004, Neubert, et al. 2013, Ocana, et
al. 2010, Whiteaker, et al. 2010, Winther, et al. 2009, Yu, et al. 2012), however, hydrophilic
interaction liquid chromatography (HILIC) has been used to separate hydrophilic peptides.
Columns used for peptide separation have particle size and dimensions similar to those used for
small molecule quantification (Arsene, et al. 2010, Barnidge, et al. 2004, Barton, et al. 2010,
Kirsch, et al. 2007, Kumar, et al. 2010, Yu, et al. 2012). However, specialized columns having
pore size around 300 Å have been used especially wherein low molecular weight proteins need
to be separated. In addition, a number of quantification approaches involving nano and micro
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flow LC systems have been carried out using capillary columns having small inner diameters
(I.D.) such as 75 and 150 µm (Ahn, et al. 2009, Keshishian, et al. 2007, Kuhn, et al. 2004,
Neubert, et al. 2013, Whiteaker, et al. 2010). Recent developments in chromatographic
hardware, mainly precise delivery pumps for micro and nano volumes, tighter system integration
to reduce dead volumes, smaller diameter columns and newer LC-MS interfaces such as the
Waters ionkey/MS separation device cartridge that holds a capillary column and a nanospray
needle, have enabled use of nano and micro LC-MS/MS systems (Arnold, et al. 2013). The nano
and micro-LC systems have better sensitivity due to higher electrospray efficiency obtained by
the use of low flow rates, In addition, these systems utilize less solvent and thus help in cost
reduction (Ahn, et al. 2009, Keshishian, et al. 2007, Kuhn, et al. 2004, Neubert, et al. 2013,
Whiteaker, et al. 2010).
Two-dimensional chromatographic separations, such as ion-exchange chromatography (IEC)RPLC or RPLC-HILIC, has been utilized to fractionate and clean up samples, thus improving
sensitivity of detection (Gilar, et al. 2005, Keshishian, et al. 2007, Liu, et al. 2009, van den
Broek, et al. 2013a, Zhang, et al. 2014). Additionally, most of the currently published methods
have used column trapping prior to analytical separation to remove salts and highly hydrophilic
peptides (Ahn, et al. 2009, Berna, et al. 2009, Callipo, et al. 2010, Kuhn, et al. 2004, Ocana, et
al. 2010, Whiteaker, et al. 2010, Winther, et al. 2009).
Most peptide LC-MS/MS quantifications are carried out using gradient mobile phase systems
containing additives such as formic acid and trifluroacetic acid (TFA). Though TFA improves
peak shape by reducing the interaction between peptides and the stationary phase, it is known to
suppress electrospray ionization intensity (Apffel, et al. 1995). Ionization suppression by TFA
can be circumvented by addition of acetic acid (0.5%) or propionic acid (1%), or by post-column
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infusion of propionic acid and isopropanol. The large excess of weak acid protonates TFA anions
back to neutral TFA molecules, thus freeing up the analyte ions from being paired with TFA
anions (Apffel, et al. 1995, Shou, et al. 2005). Studies have shown that addition of 5% DMSO as
a cosolvent can enhance ionization intensity through charge state coalescence (Meyer, et al.
2012).
1.3

ANALYTICAL VALIDATION OF BIOMARKER ASSAYS

With the increasing use of biomarkers for diagnosis, patient stratification in clinical settings and
higher acceptance of surrogate markers in clinical trials by regulatory bodies, there is a need for
a greater focus on validation of quantitative biomarker assays (Buyse, et al. 2010, Lee 2009, Lee,
et al. 2006). The objective of validating a method is to demonstrate that a particular method is
reliable for the intended purpose. The intended use of biomarker data is an important
consideration to determine the rigor of method validation. Thus, a ‘fit-for-purpose’ approach is
most suitable for biomarker validation (Lee 2009, Lee, et al. 2006). In the last few years, there
has been some consensus regarding LC-MS/MS method validation for biomarkers. Currently,
biomarker assay validations using LC-MS/MS are being carried out using USFDA bioanalytical
guidelines with intermediate acceptance criteria i.e. criteria ranging between those used for
ligand binding assays (LBA) and small molecule bioanalytical assays (Bower, et al. 2014, Lee
2009, Lee, et al. 2006, Stevenson, et al. 2013). Some aspects that need to be considered prior to
undertaking a ‘biomarker analytical validation’ are discussed below.
1.3.1 Reference Standards
A reference should have high purity and should be well characterized and should represent the
biologically relevant form of the analyte protein. Reference standards of smaller proteins like
insulin and steroid hormones are commercially available in highly purified and well
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characterized form (Lee, et al. 2006). However, most biomarkers are large proteins and their
commercially available standards are often impure, poorly characterized and may not fully
representative of the biologically relevant form. Additionally, there may be inconsistency in the
purity and form between lots and manufacturers (Lee, et al. 2009). If the reference standards are
obtained as recombinant proteins from non-eukaryotic cells, they may differ from the
endogenous form as it will not have the necessary PTMs. If there exists no reference standard or
if the reference standard is not a complete representative of the endogenous form, the method is
referred to as quasi-quantitative (Lee, et al. 2006).
1.3.2 Standard Calibrator matrix
Biomarkers are endogenous molecules and selection of a blank matrix for preparation of
calibrators and quality control samples is an important step in biomarker method validation (Lee,
et al. 2006, Lee, et al. 2007, Lee, et al. 2009). A simplified way is to pool together lots
containing low endogenous concentrations. However, this would result in measureable
concentrations of biomarker in the background and limit the evaluation of lower limits (van de
Merbel 2008). A second option is to use a surrogate matrix such as stripped plasma wherein the
endogenous levels have been removed using affinity adsorption, activated charcoal or some other
means of removal (van de Merbel 2008). A third option is to use a substitute matrix such as a
biological matrix from another species which does not produce the biomarker protein. Another
option is to use a buffer as a surrogate matrix. Use of a surrogate matrix or substituted matrix
avoids the need to continuously screen lots to identify low biomarker concentration matrices. A
disadvantage is that additional studies will need to be carried out to demonstrate the absence of
matrix effects. When using calibrators spiked with a surrogate matrix, it is essential to compare
recovery to demonstrate that the concentration-response relationships are similar. Additionally, a
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parallelism experiment is required to demonstrate that the endogenous biomarker behaves in a
similar immunochemical manner to the reference standards (Lee, et al. 2006, Lee, et al. 2007,
Lee, et al. 2009).
1.3.3 Selectivity
Selectivity is the ability of the method to determine the analyte unequivocally in the presence of
components that may be expected to be present in the sample. During method development,
selectivity is built into the method by choosing a unique signature peptide and choosing a SRM
transition that has the least interference. As biomarkers are endogenous molecules, selectivity is
evaluated by spiked recovery. To evaluate the selectivity, the basal level in individual lots is
initially screened against a calibration standard curve obtained using calibrators prepared in a
surrogate buffer matrix. The reference standard is then spiked in these lots to obtain a lower limit
of quantification (LLOQ) concentration. At least 6 lots for each population are evaluated to
account for inter-subject variability. Spiked recovery for each lot is estimated after accounting
for baseline concentrations from the measured concentrations. The spiked recovery will have to
be within a criterion set a-priori.
1.3.4 Parallelism
Parallelism is a dilutional linearity test of an authentic sample. This study demonstrates that the
endogenous analyte in the unknown sample behaves similarly regardless of dilution by the
standard matrix. Several individual samples, with high concentrations are chosen and analyzed
undiluted and with a dilution factor of 3 or 4. The ratio of the calculated results (observed
concentration x dilution factor) divided by the mean of the results are plotted against the inverse
of the dilution factor. Parallelism is demonstrated if the ratio is not affected by dilution. If
parallelism is cannot be established the method is only quasi-quantitative (Lee, et al. 2009).
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1.3.5 Specificity
Specificity is the ability of the method to distinguish between the analyte and other structurally
similar molecules (Lee, et al. 2009). Cross-reactivity during immunoaffinity isolations during
sample preparation, may result in a negative bias. If metabolites or isoforms of the biomarker
protein are known and available as standards, a study can be designed to ensure that their
presence does not have an impact on protein biomarker measurement.
1.3.6 Accuracy, precision & assay range
Many biomarker assays are developed to differentiate between healthy and diseased populations.
A ‘fit-for-purpose’ assay range that covers baseline healthy individual concentrations as well as
patient populations, is used. Additionally, dilution integrity should be established to enable
analysis of unknown samples whose concentration falls above this assay range.
Validation samples (calibration curve standards and quality control samples) are prepared using
reference standards and used for measuring intra- and inter- assay accuracy and precision.
Accuracy (expressed as percent deviation from normal (% DFN)) is the agreement between the
measured result and its theoretical true value. Precision is a quantitative measure (usually
expressed as %RSD and %CV) of the random variation between a series of measurements from
the same homogenous sample. Usually different concentrations covering the assay range are
prepared and used for validation studies. Traditionally five levels are used : 1) LLOQ (2) lower
quality control (LQC) which is approximately three times of LLOQ 3) Mid quality control
(MQC) 4) High quality control (HQC) which is within 90% of the higher end of the assay range
5) Dilution quality control (DQC) which is approximately 1.5 times the highest calibration
standard. Accuracy and precision are assessed in multiple (at least 3) validation runs processed
over different days. Each validation run is comprised of two sets of calibration curve standards
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and six replicates of quality control samples. A predefined criterion is used for acceptance of
accuracy and precision of the validation run. The criteria used often range between those used
for USFDA bioanalytical guidelines for small molecules and ligand binding assays (LBA)
(Bower, et al. 2014, Lee 2009, Lee, et al. 2006, Stevenson, et al. 2013)
1.3.7 Stability
Stability of the analyte in stock solutions and the biological matrix should be demonstrated
during validation. The analyte protein may undergo proteolytic cleavage or chemical (oxidation
or aggregation) during storage. Usually freeze-thaw stability, bench-top stability, short and long
term storage stability is established during validation. Incurred sample analysis may be
performed to establish long term stability of patient samples. During sample collection, relevant
inhibitors (protease inhibitor or platelet activation inhibitors) should be added, if degradation of
the analyte protein or conversion of precursors is known (Ahmed 2009, Lee, et al. 2009, Zhu, et
al. 2010).
1.4

CONCLUDING REMARKS

Immunoassays, primarily ELISAs, have dominated protein quantification over the last four
decades. However, due to development in mass spectrometry over the last decade, this trend has
started to shift. Mass spectrometry provides a universal platform for analysis of biomarker
proteins. In addition to providing greater selectivity, ease of multiplexing and lower development
cost, mass spectrometry based quantification of protein biomarkers has decreased biomarker
assay development time, thus, enabling acceleration of the timeline between biomarker discovery
and biomarker validation. The use of sample preparation techniques such as ‘immunoaffinity
isolations’ and ‘double extraction’ along with advancements in LC-MS/MS instrumentation has
resulted in achieving detection limits comparable to those of ELISA.
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Method development of mass spectrometry based biomarker assays involves a number of
challenges including selection of signature peptides, selection and optimization of protein
purification and digestion techniques and internal standardization. In recent years, there has been
a lot of effort from regulatory authorities and industry to build consensus on development and
validation of mass spectrometry based assays for proteins (Bower, et al. 2014, Sailstad, et al.
2014, Stevenson, et al. 2013, van de Merbel, et al. 2014). With further advancements in mass
spectrometric instrumentation, protein analysis software and sample preparation technology,
biomarker bioanalysis will be more reliable, enabling more utility in clinical settings. Accurate
and precise biomarker assays enable faster clinical decisions with regard to diagnosis and
therapy selection. More reliable biomarker analysis will also promote higher acceptance of
surrogate endpoint markers by regulatory authorities, allowing shorter clinical trials and shorter
drug development time.
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CHAPTER 2

2

DISSERTATION OBJECTIVES

Mass spectrometry is being increasingly used in biomarker research mainly due its ability to
achieve high selectivity coupled with high sensitivity (Makawita, et al. 2010, Ramanathan, et al.
2011, Rauh 2012). This research proposal focuses on quantitative mass spectrometric
investigations on protein biomarkers i.e. serum thymidine kinase 1 and human osteopontin
(OPN).
The first objective of this dissertation research will be to develop and validate a liquid
chromatography and tandem mass spectrometry (LC-MS/MS) method to quantitatively measure
the activity of thymidine kinase 1(TK1), a tumor biomarker, in human serum. Thymidine kinase
1 activity will be measured by monitoring the conversion of an exogenous TK1 substrate 3’fluorothymidine (FLT) to its phosphorylated product i.e. 3’deoxy-3’-fluorothymidine
monophosphate (FLT-MP), using LC-MS/MS. The developed analytical method will be
validated as per US FDA guidelines (Center for Drug Evaluation and Research (U.S.), et al.
2001). Application of validated method will then be demonstrated by distinguishing TK1 activity
in serum samples obtained from hepatocellular carcinoma patients along with matched controls.
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Human osteopontin is secreted plasma protein which is elevated in various cancers and is
indicative of poor prognosis (Rodrigues, et al. 2007). The second objective of this dissertation
will involve development and validation of a capillary microflow LC-MS/MS method to quantify
human osteopontin (hOPN) from plasma using a biologically relevant signature peptide. This
method will use an immunopurification for isolation of hOPN from plasma. The isolated protein
will then be digested with trypsin in the presence of an internal standard peptide to generate a
biologically relevant signature peptide i.e. GDSVVYGLR. Preliminary studies showed that the
peptide yields decreased with increased digestion time indicating signature peptide instability. A
specific aim of this part of research would be the evaluation of a SIL peptide and an extended
SIL peptide as internal standards to track digestion variability.
The third research objective will be to develop an in vitro method for evaluating the
cardiovascular risk potential of tobacco products by measuring the levels of secreted osteopontin
and its metalloproteinase-3 (MMP-3) cleaved N-terminal fragment in the media of tobacco
extract exposed endothelial cells. In order to achieve this objective, a method will be developed
to simultaneously measure human osteopontin and its metalloproteinase-3 (MMP-3) cleaved Nterminal fragment from cell culture media.
The fourth objective of this dissertation will be to evaluate the use of peptide standards as
internal standards to compensate for the immunocapture variability during LC-MS/MS
quantification of a biomarker protein. We hypothesized that an extended SIL-IS peptide could be
used to compensate for immunocapture variability during protein quantification provided that
immunocapture is carried out with an antibody that binds to a common epitope present on both
the protein and SIL-IS peptide. In this proof of concept investigation, we evaluate the ability of
an extended SIL-IS peptide to compensate for immunocapture variability using a hOPN specific
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antibody (MAB222P) that has an epitope in the signature peptide region (DSVVYG) of the
protein.
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CHAPTER 3

3

LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY METHOD
FOR QUANTIFICATION OF THYMIDINE KINASE ACTIVITY IN HUMAN
SERUM BY MONITORING THE CONVERSION OF 3’DEOXY-3’FLUOROTHYMIDINE TO 3’DEOXY-3’-FLUOROTHYMIDINE
MONOPHOSPHATE.

Drawn from published paper (Faria, et al. 2012)

3.1

INTRODUCTION

Thymidine kinase 1 (TK1, ATP; Thymidine 5’-phosphotransferase; EC.2.7.1.21) is a key cellular
enzyme in DNA synthesis which catalyzes the one step pyrimidine salvage pathway (Bradshaw,
et al. 1984). Specifically, TK1 catalyzes the transfer of terminal phosphate from ATP to the 5’
hydroxyl group of deoxythymidine (dThd) to produce deoxythymidine monophosphate (dTMP).
Increased activity of serum or plasma TK1 has been reported in diseases involving DNA
metabolism, e.g., viral infections (Gronowitz, et al. 1984, Gronowitz, et al. 1986), vitamin B12
deficiency (Gronowitz, et al. 1984) and in a variety of malignant diseases including acute and
chronic leukemia(Hagberg, et al. 1985), Hodgkin’s disease (Eriksson, et al. 1985), non33

Hodgkin’s lymphoma (Hallek, et al. 1992, Topolcan, et al. 2008) , lung cancer (Topolcan, et al.
2008) and ovarian cancer (Hallek, et al. 1997, Topolcan, et al. 2008). TK1 also phosphorylates
derivatives of thymidine or deoxyuridine (dUrd). In particular, TK1 can phosphorylate
nucleotide analogs with modifications at the 5'-position of the pyrimidine ring, and the 3'position

of

the ribose including

5-fluoro-2’-dideoxythymidine

and

3'-azido-3'-

deoxythymidine (Zidovudine) (Eriksson, et al. 1991, Furman, et al. 1986). These nucleotide
analogs can therefore be used to monitor the activity of TK1 (Gronowitz, et al. 1984, Ohrvik, et
al. 2004, Topolcan, et al. 2008). For example,

18

F-3’deoxy-3’-fluorothymidine (18F-FLT), has

been used to monitor tumor proliferation via positron emission tomography (Rasey, et al. 2002,
Salskov, et al. 2007, Toyohara, et al. 2002). Phosphorylation of FLT by TK1 leads to cellular
trapping and accumulation of FLT-monophosphate (FLT-MP) without incorporation into DNA.
Since FLT has low affinity for TK2 in comparison with FLT-MP, it acts as a selective substrate
to monitor TK1 activity (Eriksson, et al. 1991, Munch-Petersen, et al. 1991).
Serum TK1 activity can reflect tumor burden and proliferation, and is most commonly measured
using a commercially available thymidine kinase radioenzymatic assay (TK-REA), which uses
125

I-deoxyuridine as a substrate to measure thymidine kinase 1 activity (Gronowitz, et al. 1984).

This assay is time-consuming and requires radioactive waste management. A competitive
enzyme-linked immunosorbent assay (ELISA) has also been used for measuring serum TK1
activity for measuring phosphorylation of the selective TK1 substrate
deoxythymidine (AZT)

3'-azido-2'-

(Ohrvik, et al. 2004). Alternatively, 5-bromodeoxyuridine (BrdU)

incorporation into DNA can be monitored by ELISA (Gronowitz 2007). After phosphorylation
by TK1, bromodeoxyuridine monophosphate (BrdUMP) is processed to bromodeoxyuridine
triphosphate (BrdUTP) by yeast enzymes, and the BrdUTP is immobilized by incorporation into
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an immobilized DNA strand using a recombinant reverse transcriptase. Further, the amount of
BrdUTP incorporated in DNA is estimated using an ELISA. This assay is more sensitive than
the assay using AZT as a substrate (Gronowitz 2007). However, complex sample processing,
reagent expense, and selectivity issues associated with ELISA methods are limitations to its
application.
Quantification of nucleotide analogues can be performed using high performance liquid
chromatography (HPLC) with ultraviolet or fluorescence detection (Jancita, et al. 1980, Serve, et
al. 2010). In the last decade, mass spectrometric (MS) detection has increasingly been used for
quantification of nucleoside and nucleotide analogs (Banoub, et al. 2005, Cohen, et al. 2009).
Mass spectrometry allows extremely specific and sensitive quantification of nucleotide analogs
from biological matrices including serum. Thus, LC-MS/MS can be used as a tool to measure the
conversion of FLT to FLT-MP in serum.
In our previous work, a method was developed to quantify the intracellular conversion of FLT to
FLT-MP in cell lysates using LC-MS/MS (Li, et al. 2011b). Separation of the analytes was
achieved using C18 column and detection using Applied Biosystems SCIEX API 4000 QTrap
mass spectrometer. This method was able to monitor proliferating cell TK1 activity in as few as
500 cells per well in LNCaP prostate cancer cells. In the present report, we describe the
development and analytical validation of a suitable non-isotopic, non-immunologically based
assay for quantitative monitoring of FLT to FLT-MP in human serum (See Figure 3-1). This
method uses a labeled isotope internal standard, and column trapping to improve assay
ruggedness.
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Figure 3-1: Illustration showing the conversion of FLT to FLT-MP by thymidine kinase 1.
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3.2

MATERIALS AND METHODS

3.2.1 Chemicals and reagents
HPLC grade acetonitrile and methanol were purchased from Honeywell Burdick & Jackson
(Muskegon, MI, USA). 3’-Deoxy-3’fluorothymidine was purchased from Sigma Aldrich (St.
Louis, MO, USA). 3’-Deoxy-3’fluorothymidine-5’-monophosphate disodium salt (FLT-MP), 3’Deoxy-3’fluorothymidine-d3 (FLT -d3) and 3’-Deoxy-3’fluorothymidine-5’-monophosphate-d3
(FLT-MP-d3) were purchased from Toronto Research Chemicals Inc. (TRC, Toronto, ON,
Canada). Citric acid, formic Acid, sodium acetate, adenosine 5’-triphosphate (ATP), uridine 5’monophosphate (UMP) , magnesium chloride (MgCl2) and dithioerythritol (DTE) were obtained
from Sigma-Aldrich (St. Louis, MO, USA). High purity water was obtained in-house using a
NANOpure Diamond Life Science ultrapure water System from Barnstead International
(Dubuque, IA, USA). Nitrogen was obtained from a Parker Balston Tri Gas Generator LCMS5000 (Haverhill, MA, USA). Microcentrifuge tubes (1.5ml) and disposable glass centrifuge
(10ml) were purchased from VWR International (Westchester, PA, USA). Human serum was
obtained from Biochemed Services, Inc. (Winchester, VA, USA).
3.2.2 Instruments and HPLC conditions
High performance liquid chromatography (HPLC) separations were performed using the
following equipment: Shimadzu system controller SCL-10A VP, pumps LC-10AD VP, solvent
degasser DGU14A (Shimadzu, Kyoto, Japan) and a Waters Acquity UPLC® system (Waters
Corporation, Milford, USA). Phenomenex Security Guard column (Gemini C18, 4× 2.0mm, 5
μm) from Phenomenex (Torrance, CA, USA) was used as the loading column and an Aquasil
C18 column (100mm×2.1mm I.D., 5 μm) from Thermo Scientific (Waltham, MA, USA) was
used as the analytical column. The analytical column was maintained at 40°C.
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Sample loading was achieved using a Waters Acquity UPLC® system. Pumps A and B delivered
loading mobile phase A (0.1% formic acid) and loading mobile phase B (0.1% formic acid in
acetonitrile), respectively. Sample loading was carried out with 100% loading mobile phase A
maintained at a flow rate of 0.300 ml/min. Following an initial loading time of 1.5 min, the
diverter valve was switched to position B and the elution initiated.

A 10-port Cheminert

switching valve and a microelectric actuator obtained from Valco Instruments Co. Inc. (Houston,
TX, USA) was used to divert flow to the analytical column in position B. After a running time
of 5 minutes, the diverter valve position was switched back to allow flushing of the loading
column. The flushing of the loading column was carried out at 0.400ml/min with 50% loading
mobile phase B. After flushing for one minute, the loading mobile phase composition was
changed back to 100% loading mobile phase A pumped at a flow rate of 0.300 ml/min. Elution
was carried out under gradient conditions using two Shimadzu pumps which were operated with
a Shimadzu system controller. The elution mobile phases consisted of 0.1 % formic acid in water
(A) and 0.1 % formic acid in acetonitrile (B). The flow rate was set to 0.300 ml/min. Gradient
conditions were as follows: 0.0 –2.0 min, isocratic 5% B; 2.00 –4.0 min, linear from 5% to 75%
B; 4.1 –7 minutes, isocratic 5% B. The total running time was 7 minutes and the injection
volume was 25 µL. The column switching LC-MS/MS design is shown in Figure 3-2.
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Figure 3-2: Column switching LC-MS/MS design
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3.2.3 Mass Spectrometry conditions
Mass spectra were obtained using an Applied Biosystems SCIEX API 4000 QTrap mass
spectrometer operated in positive electrospray ionization mode (ESI). Tuning and optimization
of the mass spectrometer parameters were performed for the analytes and internal standard (IS,
see below) by direct infusion of a 1 µg/mL standard solution at a flow rate of12 µL/min. The
multiple reaction monitoring (MRM) transitions, declustering potential (DP) entrance potential,
collision energy (CE) and collision cell exit potential (CXP) for all the compounds are listed in
Table 3-1.

The mass spectrometric parameters were as follows: ion source temperature

(TEM=450°C), ion transfer voltage (IS=5500 V), collision gas (CAD=high), curtain gas
(CUR=20), ion source gas 1 (GS1=55) and ion source gas 2 (GS2=45). The units for gases are
arbitrary. The data were acquired with Analyst software, Version 1.5.
3.2.4 Preparation of stock solutions, standards and quality control samples
Stock solutions were prepared by dissolving FLT and FLT-MP in methanol to yield 12.5 and 50
µg/mL solutions, respectively. Intermediate stock solutions were prepared by further diluting the
stock solution in methanol to prepare spiked serum samples. Internal standard stock solutions
were prepared by dissolving FLT-d3 and FLT-MP-d3 in methanol to yield a concentration of 500
μg/mL. A working IS solution (final concentration of 200 ng/mL) was subsequently prepared by
diluting the stock solutions of each compound in methanol. Stock solutions, QC solutions and IS
solutions were stored at -20°C.
3.2.5 Preparation of calibration standards and quality control samples in human serum
Calibration standards and quality control samples were freshly prepared daily by spiking
working solutions and quality control solutions in pooled human serum. The concentration range
of the calibration standards was FLT (0.500-500 ng/mL) and FLT-MP (2.5-2000 ng/mL). The
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quality control samples (Lower limit of quantification (LLOQ), Low quality control (LQC),
Medium quality control (MQC), High quality control (HQC) and dilution quality control ) had
the following concentrations: FLT (0.50, 2.00, 40, 375 and 2000 ng/mL) and FLT-MP (2.50,
6.00, 60, 1800 and 5000 ng/mL).
3.2.6 Preparation of Phosphorylation Buffer and Reconstitution Solution
Phosphorylation buffer was prepared fresh prior to sample analysis. The buffer comprised 0.1 M
sodium acetate, 7.8 mM ATP, 2 mM UMP, 12mM DTE and 30 mM MgCl2 in HPLC grade
water. Reconstitution solution was prepared by dissolving 19.2 mg of citric acid and 37.2 mg of
EDTA in 100 ml HPLC grade water to obtain a mixture of 1mM Citric acid and 0.5 mM EDTA.
This was used for reconstituting the samples prior to injection on to LC-MS/MS system.
3.2.7 Sample preparation
A 50 µl aliquot of serum (samples, calibration and quality control samples) was added to a1.5 ml
microcentrifuge tube containing 50 µl of phosphorylation buffer solution. 10 µl of freshly
prepared FLT (10 µg/ml), in phosphate buffered saline (PBS), was transferred to the
microcentrifuge tubes containing serum samples, whereas 10 µl of PBS alone was transferred to
the microcentrifuge tubes containing calibration standards and quality controls. The samples
were incubated for 2 hours at 37ºC in Labline Orbit Shaker Bath model 3540 (Melrose Park,
ILIL, USA) at 125 rpm. The reaction was terminated by addition of 300 µl of methanol to each
tube. The calibration standards and quality control samples were not incubated; instead the
reaction was terminated immediately by addition of 300 µl of methanol to each tube. To each
tube, 50 µL of internal standard was added and the tube was vortex mixed for 2 minutes and
centrifuged for 10 min. at 4ºC/10,000 rpm using an Eppendorf centrifuge model 5805 (Hamburg,
Germany). Approximately, 400 µL of supernatant was transferred into a 10 ml disposable glass
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centrifuge tube and evaporated to dryness under nitrogen gas at 50°C for ~15minutes. The
samples were reconstituted with 50 µL of a reconstitution solution. The reconstituted samples
were transferred to a 1 mL 96-well plate and analyzed by LC-MS/MS.
3.2.8 Matrix effects
In order to evaluate matrix effects, a post-column infusion study was conducted. A 100 ng/mL
solution (FLT and FLT-MP) in methanol was prepared and continuously infused at 20 µL/min
post HPLC column directly into the mass spectrometer using a “tee” connection.

After

stabilization of the baseline, a blank sample was injected and the profiles were investigated for
suppression or enhancement at the retention time of FLT and FLT-MP.
3.2.9 Validation procedures
Validation of the assay was performed according to the FDA guidelines for Bioanalytical
Method Validation (Center for Drug Evaluation and Research (U.S.), et al. 2001). Validations
runs containing duplicate calibration standards, blank samples, and blank sample spiked with
internal standard and replicates of QC samples were run on three separate days.
3.2.9.1 Selectivity
Human serum samples from six different sources were analyzed in duplicate along with spiked
LLOQ serum calibration standards to evaluate selectivity of the analytical method.

Each

individual lot was extracted according to the sample preparation procedure for calibration
standards and quality control samples given above. Selectivity requirements were that any peak
area co-eluting at the retention time of analytes (FLT/FLT-MP) must be less than 20% of the
peak area of the average of LLOQ samples for all six lots of blank serum samples. Additionally,
any peak area co-eluting at the retention time of internal standards (FLT-d3 and FLT-MP-d3)
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must be less than 5% of the average peak area of the internal standard concentration for all six
lots of blank serum samples.
3.2.9.2 Linearity and LLOQ
Eleven calibration standards were extracted in duplicate and analyzed in 3 independent runs.
Calibration curves were fitted using linear regression of the ratio of the peak area response of the
analyte and the internal standard versus concentration. A weighting factor of 1/x2 was used for
both the analytes (FLT and FLT-MP). The acceptance criteria followed FDA guidelines for
bioanalytical method validation [22].
3.2.9.3 Accuracy and precision
Accuracy and precision were determined from QC samples (LQC, MQC, HQC, dilution QC) in
three independent runs. A criterion of ±15% of the nominal concentration was used to assess
accuracy and precision was expressed as %RSD, which should not exceed ±15%. Intra-assay
precision and accuracy were determined from 6 replicates of each QC sample on a single assay.
Inter-assay precision and accuracy were determined by analyzing three different validation runs.
3.2.9.4 Recovery and carryover
Analyte recovery of the extraction procedure was determined by comparing peak areas. Blank
serum was spiked with FLT and FLT-MP at two levels (LQC and HQC). These samples were
compared to samples spiked after extraction with the same final concentrations of FLT and FLTMP to compensate for variations in instrument response. The criterion for acceptance in this
recovery experiment was that recovery was consistent over the two QC levels. Carry over was
assessed by injecting LQC immediately after each of the highest calibration standards in an
analytical run. The acceptance criterion for this experiment was that the LQC must be accurate
to within 15% of the nominal concentrations.
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3.2.9.5 Stability Studies
Post-preparative stability was assessed using blank serum samples spiked with FLT and FLT-MP
at two levels LQC and HQC. These quality control samples were processed and maintained at
5°C in the autosampler. After 48 hours, these samples were analyzed against a freshly spiked
calibration standard curve. A criterion of ±20% of the nominal concentration was used to assess
for 48 hours post-preparative stability. Additionally, the intermediate stability of samples, i.e.
supernatant, was assessed. Spiked serum LQC and HQC samples of FLT and FLT-MP were
processed as described above. The supernatant (400 μl), obtained after protein precipitation and
vortex mixing, was transferred to a 10 ml disposable glass centrifuge tube, then stored at 4°C.
After 48 hours, the supernatant was processed and analyzed against a freshly spiked calibration
standard curve. A criterion of ±20% of the nominal concentration was used for intermediate
stability.
3.2.9.6 Precision of the FLT Phosphorylation reaction
In order to assess the precision of the phosphorylation procedure, a serum sample having high
TK1 activity (serum H) was diluted with a serum sample having low TK1 activity (serum L) to
obtain six different control concentrations as follows : 1) Undiluted serum H 2) Serum H diluted
2 times with serum L 3) Serum H diluted 5 times with serum L 4) Serum H diluted 10 times with
serum L 5) Serum H diluted 25 times with serum L 6) Undiluted serum L. Six replicates were
analyzed and assay precision was expressed as %RSD for each control concentration. The serum
sample with high TK1 activity (serum H) was defined arbitrarily to have an activity equivalent to
1 while the serum sample having low TK1 activity (serum L) was defined as an activity
equivalent to 0. Activity units for the six levels were calculated based on the ratio of the activity
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of serum H to serum L. These activity units were used to correlate TK1 with the amount of FLTMP generated at the end of 2 hour incubation at 37°C
3.2.10 Application of the validated method
The validated method was used for determination of TK1 activity in 19 serum samples obtained
from hepatocellular carcinoma patients and 40 healthy, age-matched controls (20 male and 20
female; Bioreclamation Inc., Westbury, NY, USA).

3.3

RESULTS AND DISCUSSION

This serum TK1 activity assay monitors the phosphorylation of FLT, a thymidine analog and
selective TK1 substrate, to its metabolite FLT-MP. The reaction is performed at 37°C in a 0.1M
sodium acetate phosphorylation buffer supplemented with enzyme co-factors and stabilizing
reagents (Karlstrom, et al. 1990, Ohrvik, et al. 2004). ATP serves as a phosphate donor in the
reaction. The reducing agent DTE liberates TK1 from inhibitory serum protein complexes, and
UMP serves as a FLT-MP degradation inhibitor [11]. The FLT phosphorylation FLT
phosphorylation reaction is terminated by methanol extraction. Calibration and quality control
standards were freshly prepared to avoid analyte degradation in human serum that can occur after
extended storage [11]. Since recombinantly produced TK1, and TK1 generated from cell lysates
may not be biochemically representative of TK1, serum with high endogenous TK1 activity was
diluted with low-activity serum to serve as positive controls (Rasey, et al. 2002, Salskov, et al.
2007). Target analytes were extracted using protein precipitation, and chromatographically
separated using a column switching strategy. Specifically, samples were loaded onto a C18
Phenomenex security guard column, which retains the analytes while impurities were eluted to
waste. After column switching, analytes were separated on an Aquasil C18 analytical column
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and detected using the QTrap in MRM mode. Without column switching, a build-up of matrix
on the column after multiple injections was observed, which resulted in a loss of sensitivity (data
not shown).
LC-MS/MS conditions were optimized for the analytes (FLT, FLT-MP, FLT-d3 and FLT-MPd3), allowing their quantification with a total run time of 7 min. Retention times and mass
transitions are shown in Table 3-1. Representative chromatograms of blank samples for FLT and
FLT-MP are shown in Figure 3-3 and 3-4, respectively. Representative chromatograms of FLT
and FLT-MP at the LLOQ are shown in Figure 3-5 and 3-6, respectively. Matrix effects were
evaluated with post-column infusion of a 100 ng/mL FLT and FLT-MP solution. No suppression
or enhancement was seen at retention time of analyte peaks.
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Table 3-1:Mass Spectrometer Parameters and Approximate Retention Times
Analyte

Retention

Multiple Reaction

DP

EP

CE

CXP

Time

Monitoring Transitions

( Volts)

( Volts)

( Volts)

( Volts)

(mins)

(Parent ion → Product
ion)

FLT

3.95

245.1 → 127.1

40

10

20

10

FLT-d3

3.95

248.0 → 130.2

40

10

20

10

FLT-MP

3.53

325.3 → 81.2

50

10

28

10

FLT-MP-d3

3.53

328.1 → 81.2

50

10

28

10
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Figure 3-3: Representative chromatogram of serum blank (FLT and FLT-d3)
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Figure 3-4: Representative chromatogram of serum blank (FLT-MP and FLT-MP-d3).
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Figure 3-5 : Representative chromatogram of Lower limit of Quantification(LLOQ) of FLT
and FLT-d3.
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Figure 3-6 : Representative chromatogram of Lower limit of Quantification(LLOQ) of FLTMP (LLOQ) and FLT-MP-d3
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3.3.1 Validation of the analytical method
3.3.1.1 Selectivity
The peak area at the retention time for all the analytes in the six human serum lots was found to
be less than 10% of the respective LLOQ serum calibration standard. Thus, indicating that the
method was selective estimating FLT and FLT-MP from human serum samples.
3.3.1.2 Linearity
The peak area ratio of FLT to FLT-d3 and FLT-MP to FLT-MP-d3 were linear over the range
0.5-500 ng/mL and 2.5-2000 ng/mL, respectively.

The calibration curves yielded a mean

correlation coefficient of 0.9964 and 0.9935 for FLT and FLT-MP, respectively (n=3). A
weighting factor of 1/x2 was used for both analytes (FLT and FLT-MP). The back calculated
concentrations of the calibration curve standards in the validation runs are summarized in Table
3-2 and 3-3. The percent deviation from nominal (%DFN) for the mean back-calculated values
of the calibration standards were between -14.7% and 11.7% for FLT and -4.3% to 7.5% for
FLT-MP. Precision of the calibration standards, measured as the percent relative standard
deviation for the mean back-calculated values, ranged between 6.0% to 13.4% for FLT and 3.5%
to 14.1% for FLT-MP.
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Table 3-2: Summary of back calculated concentrations of FLT calibration curve standards
FLT (ng/mL)
RUN

0.50

1.00

2.50

5.00

10.0

25.0

50.0

100

250

400

500

Validation Run 1

0.402

A

1.85

4.96

12.5

27.2

60.8

101

226

386

431

A

0.85

2.58

4.86

10.3

23.9

50.4

92

246

434

A

0.459

0.96

2.15

4.75

10.3

27.3

53.2

89

217

317

399

0.443

0.86

2.45

5.71

10.9

27.5

52.7

107

273

413

451

A

0.718

2.37

4.85

11.5

24.4

50.7

89

230

A

485

0.42

0.875

2.73

5.60

11.5

27.3

55.7

113

A

384

523

Mean

0.43

0.85

2.36

5.12

11.2

26

54

98

238

387

458

StdDev

0.03

0.09

0.32

0.42

0.8

1.7

3.9

10.2

22

%RSD

6.0

10.3

13.4

8.2

7.6

6.3

7.2

10.4

9.2

11.4

10.5

%DFN

-14.0

-14.7

-5.8

2.4

11.7

5.1

7.8

-1.6

-4.6

-3.3

-8.4

Validation Run 2

Validation Run 3

A = deleted from calculations per SOP criteria of ± 15% (20% for LOQ)

53

44 47.99

Table 3-3: Summary of back calculated concentrations of FLT-MP calibration curve
standards
FLT-MP(ng/mL)
RUN

2.50

5.00

10.0

25.0

50.0

100

250

500

1000

1850

2000

Validation Run 1

2.38

4.32

9.05

21.8

52.2

93.4

265

499

973

1810

1990

A

5.45

10.5

27.0

49.5

109

246

552

1070

1890

1900

2.62

4.34

8

22.9

51.5

107

267

564

1040

1900

2010

2.60

4.94

11.1

26

52.4

109

252

561

937

1730

1920

2.96

5.05

9.13

24.9

41.5

87.9

241

494

1360

1610

1830

2.88

5.07

10.5

25.4

51.4

88.1

232

466

1030

1680

1890

Mean

2.69

4.86

9.7

24.7

49.8

99

251

523 1068 1770 1923

StdDev

0.23

0.45

1.2

2.0

4.2

10.4

14

42

151

117

67

%RSD

8.7

9.2

12.1

7.9

8.4

10.5

5.5

7.9

14.1

6.6

3.5

%DFN

7.5

-2.8

-2.9

-1.3

-0.5

-0.9

0.2

4.5

4.5

-4.3

-4.3

Validation Run 2

Validation Run 3

A = deleted from calculations per SOP criteria of ± 15% (20% for LOQ)
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3.3.1.3 Accuracy and Precision
The lower limit of quantification (LLOQ) was established at 0.5 ng/mL for FLT with a precision
of 8.8%. The LLOQ for FLT-MP was set at 2.5 ng/mL with a precision of 11.5%. Accuracy at
the LLOQ was -9.2% and -3.8% for FLT and FLT-MP, respectively. Inter- and intra-assay
precision and accuracy for FLT and FLT-MP quality control samples are shown in Table 3-4.
3.3.1.4 Extraction recovery and Carryover studies
The mean extraction recovery for FLT in human serum, determined at the LQC and HQC levels,
was 103.5% and 100.3%, respectively. FLT-MP mean extraction recovery was 57.0% and
56.9% for LQC and HQC, respectively.
All the LQCs were within 15% of the nominal concentrations when injected after a high
calibration standard for both analytes (FLT and FLT-MP). Thus, illustrating that carryover is not
significant for this method.
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Table 3-4: Inter-assay and Intra-assay precision and accuracy for FLT and FLT-MP.
Nominal Concentration (ng/mL)
2.0

40.0

375

2000

2.0±0.2

40.0±5.9

377.0±39.0

1830.0±84.0

Inter-assay precision (%RSD)

9.4

14.9

10.4

4.6

Inter-assay accuracy (%DFN)

-0.2

-1.1

0.4

-8.5

Intra-assay mean ± SD (n= 6)

2.1±0.2

45.0±2.6

378.0±14.0

1797.0±50.0

Intra-assay precision (%RSD)

7.7

5.9

3.6

2.8

Intra-assay accuracy (%DFN)

3.5

11.6

0.9

-10.2

6.0

60.0

1800.0

5000.0

1939.0±95.

5159.0±342.

Observed

FLT

Concentration

(ng/mL)
Inter-assay mean ± SD

Observed

FLT-MP

Concentration

(ng/mL)

Inter-assay mean ± SD

6.6±1.0

65.0±5.7

0

0

Inter-assay precision (%RSD)

14.6

8.8

4.9

6.6

Inter-assay accuracy (%DFN)

9.4

7.8

7.7

3.2

1958.0±64.

5275.0±304.

Intra-assay mean ± SD (n =6)

6.7±0.3

66.0±2.5

0

0

Intra-assay precision (%RSD)

4.4

3.7

3.3

5.8

Intra-assay accuracy (%DFN)

11.8

10.4

8.8

5.5

SD = Standard Deviation, %DFN = percent deviation from nominal value, %RSD = percent
relative standard deviation. Samples were diluted 10-fold for the FLT (2000 ng/mL) and FLTMP (5000 ng/mL) controls.
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3.3.1.5 Post preparative stability
For FLT, %DFN for the mean back-calculated values of the quality control standards were
between -20.0% and -10.2% for LQC and -10.5% to -5.5% for HQC. For FLT-MP, %DFN for
the mean back-calculated values of the quality control standards were between -9.3% and -6.3%
for LQC and 1.5% to 2.8% for HQC. Thus, post-preparative stability was found to be within the
acceptance criteria.
3.3.1.6 Intermediate processing stability
For FLT, %DFN for the mean back-calculated values of the quality control standards were
between -14.6% and -13.2% for LQC and -2.0% to -3.0% for HQC. For FLT-MP, %DFN for
the mean back-calculated values of the quality control standards were between -13.1% and -8.6%
for LQC and 19.0% to 9.0% for HQC. Thus, the supernatant obtained during processing was
considered stable within specifications when stored at 4°C for 48 hours.
3.3.1.7 Precision of the FLT phosphorylation reaction
Phosphorylation reaction precision (% RSD) was within 15% at all concentrations except the
defined zero level (Table 3-5). Additionally, the average concentration of FLT-MP in these
samples and TK1 activity were found to have a positive linear correlation with a correlation
coefficient of 0.9862 (See Figure 3-7).
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Table 3-5: Precision of the FLT phosphorylation reaction.

TK1 Activity Units*

Enzyme

Enzyme

Enzyme

Enzyme

Enzyme

Enzyme

Level-1

Level-2

Level-3

Level-4

Level-5

Level-6

1.00

0.50

0.20

0.10

0.04

0.00

965.33

599.80

245.80

131.83

58.05

5.09

SD

34.915

60.726

32.980

14.662

4.972

1.273

%CV

3.62

10.12

13.42

11.12

8.56

25.03

Average concentration
of FLT-MP (ng/ml)**

* The serum sample with high TK1 activity (serum H) was defined arbitrarily to have an activity
equivalent to 1 while the serum sample having low TK1 activity (serum L) was defined as an
activity equivalent to 0. Activity units for the six levels were calculated based on the ratio of the
activity of serum H to serum L. ** The FLT-MP concentrations were generated under
standardized conditions of 2 hour incubation at 37°C.
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Average FLT-MP Concentration
(ng/ml)

y = 969.38x + 37.042
R² = 0.9867

1000.0
800.0
600.0
400.0
200.0
0.0
0.00

0.10

0.20

0.30

0.40

0.50

0.60

0.70

0.80

0.90

TK1 Activity Units
Figure 3-7: Plot of average FLT-MP concentration formed versus TK1 activity.
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1.00

3.3.2 Application of the method to patient samples
Average FLT-MP generation in serum from healthy male and female volunteers aged 50 or older
was 19.1±10.5 ng/ml and 18.7±5.8 ng/ml, respectively when analyzed using the standardized
reaction conditions described here (37◦ C, 2 hours).
The average FLT-MP concentration in healthy individuals was 18.9 ± 8.5 ng/ml. In contrast, the
hepatocellular carcinoma patient serum samples showed a relatively wide variation in TK1
activity as seen by the varying of FLT-MP concentrations (11.7-1350.5 ng/ml). A comparison of
FLT-MP concentrations between the hepatocellular carcinoma (HCC) patient samples and the
matched controls is seen in Figure 3-8. From this figure, it can been seen that a sub-population of
the HCC patient samples demonstrated almost a 20 fold increase in TK1 activity. The increased
TK1 activity in the HCC sub-patient population may have been due to differences in the severity
of their disease although this could not be verified since detailed information regarding these
samples was not available.
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Figure 3-8:Comparison of serum TK1 activity in hepatocellular carcinoma (HCC) patient
samples & matched controls.
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3.4

CONCLUSIONS

Serum TK1 activity is a potentially useful biomarker for monitoring haematological
malignancies and solid tumors. A sensitive, non-radiometric LC-MS/MS assay for was
developed and validated for monitoring the conversion of FLT to FLT-MP in human serum.
Based on established, radiometric TK1 activity assays, this novel method shows good linearity
and selectivity in human serum samples. Stability studies demonstrated adequate intermediate
processing and post-preparative analyte stability.
The applicability of the method for measuring serum TK1 activity was demonstrated in
hepatocellular carcinoma patient serum samples and age-matched control sera. Significantly
higher concentrations of FLT-MP were found in 26.3% of the hepatocellular carcinoma patient
samples in comparison with controls. This method is proposed as an alternative to ELISA and
radio-enzymatic assays for rapid and selective determination of serum TK1 activity.
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CHAPTER 4

4

COMPARISON OF A STABLE ISOTOPE LABELED (SIL) PEPTIDE AND AN
EXTENDED SIL PEPTIDE AS INTERNAL STANDARDS TO TRACK DIGESTION
VARIABILITY OF AN UNSTABLE SIGNATURE PEPTIDE DURING
QUANTIFICATION OF A CANCER BIOMARKER, HUMAN OSTEOPONTIN,
FROM PLASMA USING CAPILLARY MICROFLOW LC-MS/MS.

Drawn from manuscript submitted to J. Chromatography B., June 2014

4.1

INTRODUCTION

Human osteopontin (hOPN) is a matricellular protein that mediates diverse biological functions
(Lund, et al. 2009). It is involved in normal physiological processes and is implicated in the
pathogenesis of a variety of disease states, including atherosclerosis, cancer, and several chronic
inflammatory diseases (Lund, et al. 2009, Rodrigues, et al. 2007, Waller, et al. 2010). It is
reported to play a major role in tumor promotion mechanisms including cell survival, adhesion,
migration, invasion and angiogenesis (Rodrigues, et al. 2007). Over expression of hOPN has
been found in a variety of cancers, including breast cancer, lung cancer, colorectal cancer,
stomach cancer and ovarian cancer (Rodrigues, et al. 2007). It is also secreted in serum, plasma,
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urine and other body fluids. Elevated plasma OPN levels have been associated with poor survival
in cancer patients (Rodrigues, et al. 2007). OPN primarily operates by binding to various
integrins mainly through its RGD (arginine-glycine-aspartic acid) amino acid sequence.
Integrins are

transmembrane receptors that

mediate

attachment

between

a cell and

its

surroundings. The adhesive RGD domain of OPN mediates interactions via αvβ1, αvβ3, αvβ5,
αvβ6, α8β1, and α5β1 integrins (Shimada, et al. 2005). OPN can be cleaved by thrombin near its
RGD integrin binding domain to expose a cryptic SVVYGLR amino acid sequence that can bind
to α9β1, α4β1, and α4β7 integrins (Scatena, et al. 2007). Furthermore, the cryptic site can be
further cleaved by metallomatrix proteinases (MMPs) at the glycine-lysine (167G-L) bond and by
plasma carboxypeptidase B-2 (CPB-2) at the (168L-R) bond. The impact of proteolytic
modification of OPN can promote or disrupt integrin binding, leading to altered cellular
responses (Scatena, et al. 2007, Shimada, et al. 2005) .
Immunoassays, in particular, enzyme linked immuno-sorbent assay (ELISA), have been the
method traditionally used for analysis of protein biomarkers. However, immunoassay
measurements can be variable and inaccurate due to cross-reactivity of the antibodies used, the
presence of post-translational modifications, interference due to autoantibodies and anti-reagent
antibodies, and the high-dose hook effect (Hoofnagle, et al. 2009). Different commercially
available ELISA kits for quantification of OPN have been shown to yield variable and noncomparable absolute concentrations (Anborgh, et al. 2009, Plumer, et al. 2008, Vordermark, et
al. 2006). For example, Plummer et al. compared three ELISA kits which produced >20-fold
differences in measured absolute hOPN concentrations for the same sample. Such variations can
lead to misleading interpretations resulting in unnecessary treatment or missed opportunities for
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therapeutic intervention. We therefore decided to explore an alternative platform for measuring
hOPN from plasma.
In the last decade, tandem mass spectrometry using selected reaction monitoring (SRM) is
increasingly employed for analysis of biomarker proteins (Makawita, et al. 2010). Due to the
limited mass range of most mass analyzers used for quantification, LC-MS/MS protein
quantification often involves digestion of the protein to yield peptides, including unique
signature peptides, which are then quantified along with an appropriate internal standard. Thus,
protein quantification involves a number of challenges including signature peptide selection,
protein digestion, sample enrichment and internal standardization (Makawita, et al. 2010).
The identification and selection of an appropriate signature peptide is an important aspect
method development, as the signature peptide serves as a surrogate analyte for the protein.
Utilizing the protein’s peptide map or amino acid sequence, in-silico proteolytic digestions can
be carried out using software such as Skyline software and Protein Prospector, and proteotypic
peptides can be identified using Basic Local Alignment Search Tool (BLAST) (Becker, et al.
2011, Halquist, et al. 2011b, Luna, et al. 2008, Rauh 2012).
Protein biomarker measurements are usually made from tissues or blood fractions i.e. plasma or
serum. Since blood measurements are less invasive, they are preferred over tissue measurements.
However, plasma and serum are highly complex biological fluids. In fact, in serum, 20% of
proteins comprise 99% of total protein content and the concentrations of all proteins span more
than 12 orders of magnitude (Makawita, et al. 2010). Analysis of direct digests of serum or
plasma would be ideal since it would involve minimal sample preparation. However, matrix
effects and interferences from other highly abundant proteins may adversely affect the limit of
quantification and selectivity of these mass spectrometric methods (Makawita, et al. 2010). Thus,
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sample enrichment is an essential part of most protein quantification methods. Sample
preparation for protein purification from a biological matrix prior to quantification using LCMS/MS can be categorized into three major strategies i.e. abundant protein removal,
immunoaffinity protein isolation and immunoaffinity signature peptide isolation after digestion
(Ackermann, et al. 2007). Depending on the level of purification required, one of the above
strategies or a combination of these could be used. For high and mid-abundance plasma proteins
(>100 ng/ml), abundant protein removal may be adequate for quantification (Ackermann, et al.
2007). However, quantification of low abundance (< 100 ng/ml) proteins would likely require
the use of immunoaffinity isolation.
Another important challenge in mass spectrometric protein quantification is the choice of an
appropriate internal standard (IS). An ideal IS should mimic the properties of the analyte in all
sample preparation and analysis steps. In LC-MS/MS quantifications, an IS accounts for any
losses during sample preparation as well as minimizes the effects of response fluctuations on the
mass spectrometer. During mass spectrometric quantification, a response ratio of the analyte and
the internal standard is correlated with the concentration ratio of the analyte and the internal
standard (Bronsema, et al. 2012).
For quantification of small molecules using LC-MS/MS, a stable-isotope labeled (SIL) form of
the analyte or a structural analogue can be used as an IS. However, since protein quantification
involves protein digestion, there are more options for internal standardization. A SIL form or a
structural analogue of either the intact protein or the signature peptide can be used. Alternatively,
an extended SIL-peptide, which can be cleaved to obtain SIL signature peptides, can be used as
an IS. A SIL-protein may be an ideal IS for protein quantification. However, SIL-proteins are
very difficult to obtain because they require specific folding of the linear amino acid sequence, as
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well as creation of intra-molecular disulfide linkages and post-translational modification. A
method known as SILAC (Stable Isotope Labeling with Amino Acids in Culture) can be used to
generate SIL-proteins(Ong, et al. 2002). However, the production of SIL-proteins can be limited
by cost and commercial availability (Bronsema, et al. 2012). A more commonly used internal
standard for protein quantification is a SIL-peptide with the same aminoacid sequence as the
signature peptide. A SIL-peptide is normally added following protein enrichment and prior to
digestion. It does not compensate for digestion variability but does account for subsequent
peptide analyte recovery and potential ion suppression effects (Ackermann, et al. 2007). An
extended or “winged” SIL-peptide, however (containing additional amino acid residues on one
or both ends), would be able to also track digestion, provided it is cleaved at the same rate as the
signature peptide (Bronsema, et al. 2012). In sample preparation methods involving peptide
immunoaffinity isolations, an extended SIL-peptide IS would also able to track variability and
recovery during immunocapture (Ocana, et al.).
Recently, Wu et al (2012), quantified OPN splice variants from plasma of lung cancer patients
using a combination of four OPN specific antibodies for IA protein isolation coupled with
targeted mass spectrometry (Wu, et al. 2012). However, the validation of the method was not
reported. In addition, the method used signature peptides which are reported to undergo post
translational phosphorylation.
Most LC–MS/MS bioanalytical assays are performed with conventional HPLC separations,
using 2.1-4.6 mm ID columns and chromatographic flow rates of 300–1000 μL/min, and mass
spectrometric detection using triple quadrupole instrument operating in electrospray ionization
(ESI) mode. The benefits of using microflow liquid chromatography (MFLC) were realized in
the 1970s; however, reliable hardware that meets regulated bioanalysis standards were not
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available (Arnold, et al. 2013). In recent years, accurate pumps delivering nanoflow and
microflow rates, reliable lower internal diameter columns, and improvements in nanospray ion
sources have facilitated the use of MFLC-MS/MS platforms for quantitative bioanalysis. Use of
microflow LC-MS/MS platforms (flow rate < 3 μL/min) using columns with internal diameters
less than 1 mm have resulted in increased sensitivity, reduction in sample volume and solvent
consumption (Arnold, et al. 2013, Broccardo, et al. 2013, Christianson, et al. 2013, Dijksman, et
al. 2012, He, et al. 2012, McAvoy, et al. 2014, Wang, et al. 2013, Zhou, et al. 2013).
In this paper, we describe the development and validation of a method to quantify hOPN from
plasma using a capillary microflow LC-MS/MS system. A schematic diagram of the strategy
used for osteopontin quantification with LC-MS/MS using immunoaffinity isolation is given in
Figure 4-1. The method uses immunopurification for isolation of hOPN from plasma. The
isolated protein is then digested with trypsin in the presence of an internal standard peptide to
generate a biologically relevant signature peptide i.e. GDSVVYGLR. Peptide yields decreased
with increased digestion time indicating signature peptide instability. A SIL peptide and an
extended SIL peptide were evaluated as internal standards to track digestion variability. The
signature peptide is quantified using a Waters nanoAcquity/TRIZAIC-Xevo-TQS LC-MS/MS
system.
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Figure 4-1:A schematic diagram of the strategy used for osteopontin quantification using LCMS/MS and immunoaffinity isolation.
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4.2

MATERIALS AND METHODS

4.2.1 Reference Materials
Recombinant hOPN was purchased from R&D Systems (Minneapolis, MN, USA). The OPN
signature peptide (OPN-SP), having the amino acid sequence ‘GDSVVYGLR’, was synthesized
by Elim Biopharmaceuticals (Hayward, CA, USA). A stable isotope labeled peptide having the
sequence ‘GDSVVYGLR*’, containing an arginine residue labeled with

13

C and

15

N4 was

synthesized by Thermo Scientific (Rockford, IL, USA) and used as the SIL-IS. The labeled
arginine residue resulted in a mass shift of +10 Da from the mass of the OPN-SP. Another stable
isotope labeled peptide having the sequence ‘TYDGRGDSVV*YGLRSKSKKF’, containing an
valine residue labeled with

13

C and

15

N4 was synthesized by Thermo Scientific (Rockford, IL,

USA) and used as an extended SIL-IS. The labeled valine residue resulted in a mass shift of +6
Da from the mass of OPN-SP.
4.2.2 Reagents
HPLC grade water with 0.1% formic acid and acetonitrile with 0.1% formic acid were purchased
from Honeywell Burdick & Jackson (Muskegon, MI, USA). High grade water was obtained
using a Milli-Q integral water purification system (Billerica, MA, USA). Bovine serum albumin,
dulbecco’s phosphate buffered saline, formic acid, methanol, Trizma hydrochloride (1M) and
tween 20 were purchased from Sigma-Aldrich (Saint Louis, MO, USA). Glacial acetic acid was
obtained from Macron Fine Chemicals (Center Valley, PA, USA). Sodium chloride solution
(5M) and EDTA solution (0.5M) were obtained from Ambion (Foster City CA, USA). Trypsin
Gold was obtained from Promega (Madison, WI, USA). Biotinylated antibodies specific to
hOPN (MAB193P) were obtained as a gift from Maine Biotechnology Services (Portland,
Maine, USA). Immuno-capture (IC) buffer and IC wash buffer were prepared in-house and were
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comprised of 0.1/5.0/3.0/0.2/91.7/0.1 (v//v/v/v/w) Tween 20/ Trizma HCl (1M)/ NaCl
(5M)/EDTA (0.5M)/water/ bovine serum albumin and 5.0/3.0/0.2/91.8/0.1 (v/v/v/v) Trizma HCl
(1M)/ NaCl (5M)/ EDTA (0.5M)/ water, respectively. Digestion solution, containing of 500
ng/100 µL of trypsin gold, 0.05 pg/100 µL of SIL-IS peptide and 0.68 pg/100 µL of extended
SIL-IS peptide in 50 mM ammonium bicarbonate buffer, was freshly prepared prior to digestion
for the validation studies.
4.2.3 LC-MS/MS Instrumentation
Preliminary method development studies were carried out using a conventional flow LC-MS/MS
system. The method was then transferred and validated on a MFLC-MS/MS.
4.2.3.1 Conventional flow LC-MS/MS system
High performance liquid chromatography (HPLC) separations were performed using the
following equipment: Shimadzu system controller SCL-10A VP, pumps LC-10AD VP, solvent
degasser DGU14A (Shimadzu, Kyoto, Japan) and a Waters Acquity UPLC ® system (Waters
Corporation, Milford, USA). ACE HPLC C4 column (50mm × 2.1 mm I.D., 5 μm) from
Advanced Chromatography Technologies Ltd, (Aberdeen, Scotland) was used as the trap column
and a Peptide Separation Technology (PST) XBridge BEH C18 column (100mm × 2.1mm I.D.,
5 μm) from Waters (Milford, USA) was used as the analytical column. The analytical column
was maintained at 50°C.
Trapping was achieved using a Waters Acquity UPLC® system using trap mobile phase A
(HPLC grade water with 0.1% formic acid) and trap mobile phase B (acetonitrile with 0.1%
formic acid), respectively. Trapping was carried out with 5% trap mobile phase B and
maintained at a flow rate of 0.300 mL/min. Following an initial trapping time of 0.8 min, the
diverter valve was switched to position B and the elution initiated. A 10-port Cheminert
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switching valve and a microelectric actuator obtained from Valco Instruments Co. Inc. (Houston,
TX, USA) was used to divert flow to the analytical column in position B. After a running time of
4.5 minutes, the diverter valve position was switched back and flushing of the trap column was
achieved at 0.300 mL/min with 5% trap mobile phase B. Elution was carried out using two
Shimadzu pumps operated with the Shimadzu system controller to apply the gradient conditions
and the elution mobile phases consisted of water with 0.1% formic acid (A) and acetonitrile with
0.1% formic acid (B). The flow rate was set to 0.400 mL/min. Gradient conditions were as
follows: 0.0 –1.0 min, isocratic 5% B; 2.0 –4.0 min, linear from 5% to 30% B; 4.0 –4.5 min,
linear from 30% to 80% B; 4.5 –5.0 min, isocratic 5% B. The total running time was 5 min and
the injection volume was 25 µL. The LC-MS/MS setup is illustrated in Figure 4-2.
Mass spectra were obtained using an Applied Biosystems SCIEX API 4000 QTrap Mass
Spectrometer operated in positive electrospray ionization mode (ESI). Tuning and optimization
of the mass spectrometer parameters were performed for the analytes and internal standard (IS,
see below) by direct infusion of a 1 µg/mL standard solution at a flow rate of 12 µL/min. The
multiple reaction monitoring (MRM) transitions, declustering potential (DP) entrance potential,
collision energy (CE) and collision cell exit potential (CXP) for all the compound are listed in
Table 4-1. The mass spectrometric parameters were as follows: ion source temperature
(TEM=450°C), ion transfer voltage (IS=5500 V), collision gas (CAD=high), curtain gas
(CUR=10), ion source gas 1 (GS1=30), ion source gas 2 (GS2=20), declustering potential
(DP=60 V), entrance potential (EP= 10 V), collision cell exit potential (CXP=10 V). The data
were acquired with Analyst software, Version 1.5.
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Table 4-1: LC-MS/MS parameters for API 4000 Qtrap system.
Charge

Retention

MRM Transitions

CE

State

time (mins)

(Parent ion → Fragment ion)

( Volts)

GDSVVYGLR

+2

4.2

m/z 483.9-508.6

24

GDSVVYGLR

+2

4.2

m/z 483.9-607.8

22

+1

4.0

m/z 639.3-359.4

30

Peptide

#

GDSVVY
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Figure 4-2: LC-MS/MS Instrumentation. A: Block diagram of the conventional flow LCMS/MS system. B: Block diagram of the MFLC-MS/MS system.
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4.2.3.2 Microflow LC-MS/MS system
The MFLC-MS/MS system consisted of a Waters NanoAcquity UPLC coupled to at Waters TQS mass spectrometer fitted with a prototype ion key/MS™ separation device. The separation
device consisted of a compact cartridge with an in-built capillary column having an internal
diameter of 150 µm and packed with 1.7 µm particles. HPLC grade water with 0.1% formic acid
and acetonitrile with 0.1% formic acid were used as mobile phase A1 and B1, respectively. The
LC system was operated in the trap mode using a single pump system. A Symmetry C18 Guard
Column, 300 µm x 50 mm from Waters (Milford, USA) was used as the trap column. Trapping
was carried out for 2 minutes at a flow rate of 20 µL/min using 99.5% mobile phase A1.
Analytical separation was performed on a Waters BEH 130 C18 iKey™ Separation Device
(100 mm x 150 μm I.D., 1.7 μm). Gradient conditions were as follows: 0.0–0.5 min, isocratic 5%
B1; 0.5 –3.0 min, linear from 5% to 20% B; 3.0 –5 min, linear from 20% to 30% B; 5.0 –7.0
min, linear from 30% to 95% B; 7.0 –8.4 min, isocratic 95% B; 8.4 –8.5 min, linear from 95% to
5%; 8.4 –8.5 min, isocratic 5% B. The total running time was 9 min and the injection volume
was 20 µL in the full loop mode. Initial flow rate from 0.0 to 0.5 min was kept at 0.5 μL/min to
avoid high back pressure during switch over from trapping to analysis mode. From 0.5 to 8.5
minutes, the chromatographic separation was carried out at a flow rate of 2.5 μL/min. The flow
rate was changed to 1.0 μL/min after 8.5 min. The cone voltage and collision energy were
optimized for each compound using automatic tuning (Intellistart system) in the TQ-S. The
parameters for each compound are listed in Table 4-2. The capillary voltage was 3.6 kV, the
source temperature was 100 °C, the source offset was 60 V, and the collision gas was argon.
Dwell times for all transitions were 0.044 s. The MFLC-MS/MS apparatus is diagrammatically
illustrated in Figure 4-2.
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Table 4-2: LC-MS/MS parameters for Xevo TQS System

Charge
State

Retention
time
(mins)

GDSVVYGLR

2

5.0

GDSVVYGLR

2

GDSVV*YGLR

MRM Transitions

Cone
Voltage
( V)

Collision
Energy

m/z 483.6-508.5

15

16

5.0

m/z 483.6-607.5

15

16

2

5.0

m/z 486.0-508.5

19

14

GDSVVYGLR*

2

5.0

m/z 488.6-518.4

19

14

TYDGRGDSV*VYGLRSKSKKF

3

4.6

m/z 568.6-669.4

37

16

Peptide
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(Parent ion →
Fragment ion)

(V)

4.2.4 Method Development Studies
4.2.4.1 Signature Peptide Selection
In-silico digestion studies were carried out using Protein Prospector version 5.10.9 (UCSF Mass
Spectrometry Facility California, USA). Trypsin was chosen as the proteolytic enzyme.
Following the in- silico digest, the peptides were subjected to sequence homology analysis in the
human plasma proteome using the Basic Local Alignment Search Tool (BLAST) software.
4.2.4.2 Digestion Optimization
A 50 µL aliquot of recombinant hOPN standard solution of 10 ng/mL was used for digestion
studies. Digestion was carried out in 50 mM ammonium bicarbonate buffer using three different
amounts of trypsin i.e. 5, 50 and 500 ng per sample. The samples were not reduced with
dithiothreitol (DTT) and iodoacetamide since hOPN is devoid of cysteine di-sulfide bonds.
Samples were withdrawn at various time intervals i.e. 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 10.5, 13, 20, 22,
24 hours. The reaction was terminated by adding formic acid. The samples were stored at -20°C
until analysis.
4.2.4.3 Immunocapture method optimization
4.2.4.3.1 Order of Addition
Commercially available monoclonal antibodies ‘MAB 193P’ which were specific to hOPN, and
having

affinities

for

a

site

distant

from

the

signature

peptide

i.e.

‘31QLYNKYPDAVATWLNPDPSQKQNLLAP’ were used for immunoaffinity isolation. The
biotinylated capture antibodies were immobilized on high binding capacity streptavidin coated
96 microwell plates and used for immunocapture. Three different strategies were evaluated for
the order of assembly of the immobilized antibody/immunocapture reaction. In Strategy I,
immobilization of antibody was carried out prior to OPN immunocapture. Strategy II involved
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the formation of OPN-antibody complex prior to antibody immobilization. Strategy III allowed
the antibody immobilization and immunocapture reaction to occur simultaneously. The strategy
with the highest yields was used in the final method. Recombinant human osteopontin (rhOPN)
was spiked in plasma to obtain a concentration of 50 ng/100 µL (not adjusted for baseline plasma
OPN level). Healthy volunteer plasma was randomly chosen for this experiment. Unspiked
plasma samples were processed as blanks to account for endogenous levels of OPN. JMP Pro
(version 10.0.2) software was used for statistically comparing the results. The three strategies for
immunocapture were as follows:
A) Strategy I (Immobilization – Immunocapture): In this biotinylated antibody (1 ug),
diluted in a IC buffer, was added to streptavidin coated plates and incubated for 4 hours
at room temperature on a rotary shaker. After 4 hours, the plates were washed three
times with IC wash buffer and 100 µL of the sample was added and incubated for 4 or 20
hours at on a rotary shaker. The plates were then washed and the immunocaptured protein
was digested.
B) Strategy II (Immunocapture – Immobilization): An aliquot of 100 µL of the sample was
incubated with the antibody in 1.5 mL Eppendorf® Lobind centrifuge tubes for 4 or 20
hours on a rotary shaker. After 20 hours, the samples were transferred to streptavidin
coated plates and incubated for 4 hours at room temperature on a rotary shaker. The
plates were then washed and the immunocaptured protein was digested.
C) Strategy III (Immunocapture + Immobilization): An aliquot of 100 µL of the sample
along with antibody was added to streptavidin coated plates and incubated for 20 hours
on a rotary shaker. After 20 hours, the plates were washed and the immunocaptured
protein was digested.
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4.2.4.3.2 Optimization of the amount of Antibody
The use of streptavidin coated 96-well plates as the solid support restricted the sample volume to
100 µL. On the conventional LC-MS/MS system, higher sample volumes were required to
achieve lower detection limits, hence the method was modified to use streptavidin coated beads
for immobilization. However, when the method was transferred to the MFLC-MS/MS system,
the higher sensitivity allowed switching to the 96-well plate format. To evaluate the impact to
varying the amount of antibody on the method, rhOPN was spiked in plasma having low baseline
concentrations to achieve a final concentration of 600 ng/mL and analyzed as per the sample
preparation procedure described under validation studies, with varying amounts of antibody. The
antibody amounts used were 0.031, 0.063, 0.125, 0.250, 0.500, 1.000, 2.000 and 4.000 µg per
well. Each level was analyzed in triplicate. The response was measured as the ratio of peak area
of the signature peptide to that of the internal standard.
4.2.5 Evaluation of internal standards
4.2.5.1 Comparison of digestion profiles of hOPN and internal standards
Tryptic digestion of the rhOPN along with the SIL peptide ‘GDSVVYGLR*and the extended
SIL peptide ‘TYDGRGDSVV*YGLRSKSKKF’ was carried out for 0, 1, 2, 3, 4, 5, 7, 8, 10, 14
and 25 hours.
4.2.5.2 Evaluation of forced and inherent digestion variability of hOPN using SIL-IS and
extended SIL-IS.
Recombinant protein was added to 50mM ammonium bicarbonate buffer to obtain 3 different
concentration levels i.e. 80, 200 and 500 ng. These standards were digested in replicate (n=8)
along with the two internal standards for 2, 7 and 14 hours. Digestion variability was induced
artificially by using different amounts of trypsin i.e. 100, 500 and 900 ng to attain 20%, 100%
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and 180% trypsin activity, respectively. Analyte/IS peak are ratio was used as response. Average
response was calculated from standards having 100% trypsin activity. Inherent variability was
expressed as the percent difference in the response obtained from standards with 100% trypsin
activity from the average response, whereas forced variability was measured as the percent
difference of the response of standards with 20% and 180% trypsin activity from the average
response. Brown-Forsythe test of unequal variance was used to compare the variance. As the
analysis involved 18 comparisons, a level of significance of α=0.003, obtained after Bonferroni
correction, was used.
4.2.6 Method Validation Studies
Validation was carried out using guidelines set forth in the May 2001 US FDA Guidance for
Industry – Bioanalytical Method Validation (2001, USFDA 2001). Due to the lack of an internal
standard control during the immunoaffinity isolation step, a wider accuracy and precision
acceptance criteria (20/25%) typically used for ligand-binding assays was be applied to this
validation. Both internal standards, the SIL-IS peptide and the extended SIL-IS peptide, were
added to all analysis. SIL-IS peptide was used as the primary internal standard to assess the
validity of the method. The extended SIL-IS was used to evaluate its impact on the precision of
the method. Two SRM transitions for the signature peptide were included in the final method but
only the response from fragment ion m/z 508.5 was used for quantitative analysis as it was found
to show less interference from co-eluting peptides.
4.2.6.1 Preparation of standards and quality control samples
The stock solution of rhOPN was prepared at 100 µg/mL in PBS and stored at -80°C as 50 µL
aliquots in 0.5 mL Protein LoBind tubes (Eppendorf®). Calibration standards and quality control
samples were prepared in surrogate matrix and plasma. Immuno-capture (IC) buffer was used as
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a surrogate matrix. Previously screened human plasma samples having low endogenous OPN
levels were pooled and used for preparation of plasma calibration standards and quality control
samples. The calibration standards were prepared by adding appropriate amounts of stock
solution or subsequent calibration standards to the surrogate matrix or plasma. Nominal
concentrations in surrogate matrix standards were 25.0, 52.7, 79.0, 118.5, 177.8, 266.7, 400.0,
600.0 ng/mL of hOPN. The same procedure was used for creation of quality control (QC)
samples at three concentration levels, denoted as lower limit of quantification (LLOQ) QC, low
quality control (LQC), medium quality control (MQC) and high quality control (HQC) having
concentrations of 25.0, 101.0, 235.7, 550.0 ng/mL of hOPN, respectively. The nominal
concentrations in plasma standards after adjusting for endogenous baseline concentrations were
60.8, 88.6, 114.9, 154.4, 213.6, 302.5, 435.8, 635.7 ng/mL of hOPN. The plasma quality control
(QC) samples, denoted as plasma lower limit of quantification (pLLOQ) QC, plasma low quality
control (pLQC), plasma medium quality control (pMQC) and plasma high quality control
(pHQC), had concentrations of 60.8, 101.0, 235.7 and 550.0 ng/mL respectively after adjusting
for endogenous baseline concentrations.
4.2.6.2 Sample Preparation
Biotinylated anti-hOPN monoclonal antibodies (0.5 µg/well) were immobilized on high capacity
streptavidin coated 96 well plates (Thermo scientific, USA). Samples were diluted 40 fold with
IC buffer and 100 µL of the diluted sample was added to each well. Immunocapture was carried
out at room temperature for 4 hours using a constant vortex of 450 rpm. After 4 hours, the plates
were washed 3 times with immunocapture wash buffer. Digestion was carried out by adding 100
µL of digestion solution to each well and incubating the plates at 37°C in a water bath for 14
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hours. Digestion was terminated by adding 2 µL formic acid to each well. The digested samples
were transferred a Protein LoBind 96 well plate and analyzed using LC-MS/MS.
4.2.6.3 Linearity and LLOQ
Calibration standards were extracted in duplicate and analyzed in 3 independent runs.
Calibration curves were fitted using linear 1/x2 weighted regression of the ratio of the peak area
response of the analyte and that of the internal standard versus concentration.
4.2.6.4 Accuracy and Precision
Accuracy and precision were determined from quality controls samples spiked in surrogate
matrix and in three independent runs processed on two different days. Intra-day assay precision
and accuracy were determined from QC samples of two validation runs processed on the same
day. Inter-day assay precision and accuracy were determined by analyzing three different
validation runs processed on two separate days. Primary evaluation was carried out using SIL-IS.
Extended SIL-IS was used only for comparison.
4.2.6.5 Dilution Integrity
An "over-the-curve" quality control sample, with hOPN concentration of 1035.5 ng/mL, was
prepared and used as a plasma dilution quality control sample (pDI QC). The samples were
analyzed with the sample preparation procedure after a two and four fold dilution in replicate. A
criterion of ±20% of the nominal concentration was used to assess the dilution integrity.
4.2.6.6 Stability Studies
Stability studies were assessed using QC samples spiked in surrogate and pooled plasma at two
levels LQC and HQC. For post-preparative stability, the quality control samples were processed
and maintained at 2-8°C for 9 days prior to analysis. Short term storage stability at -80 °C was
assessed after 18 days. Only plasma quality control samples were used to assess freeze-thaw
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stability after subjecting the samples to four freeze thaw cycles. To assess bench top stability,
the QC samples were thawed and left on the bench at room temperature for 24 hours. All
stability samples were analyzed against a freshly spiked calibration standard curve. The stability
studies were deemed acceptable if the coefficient of variation of the replicate determinations did
not exceed 20.0% and the accuracy of the mean value is within ±20.0% of the theoretical value
for that pool for both the QC levels.
4.2.6.7 Selectivity and Matrix Effect
Dilution of plasma samples in the surrogate matrix was used to avoid matrix inferences. Slopes
of the calibrations curve obtained from standards prepared in surrogate matrix were compared
with a calibration curve obtained from standards prepared in plasma. JMP Pro (version 10.0.2)
software was used. Slopes of the calibration curves and confidence intervals were obtained using
linear regression. Slopes were considered parallel if there was an overlap of the confidence
intervals. Parallel slopes would indicate no matrix differences between the two matrices.
Four human plasma samples from healthy volunteers and four human plasma samples from
breast cancer patients were analyzed in triplicate, both with and without fortification of hOPN at
the LLOQ-level. Additionally, these samples fortified with only internal standards were also
analyzed. Selectivity requirements were that any peak area co-eluting in the unfortified plasma
samples at the retention time of the internal standards must be less than 5% of the average peak
area of the individual internal standards. Spike recovery was assessed after subtraction of the
basal concentrations and the percent deviation from nominal (%DFN) was evaluated using an
acceptance criterion of ±25 %.
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4.2.7 Evaluation of internal standards ability to account for digestion variability in the
final method
Digestion variability was induced using different amounts of trypsin during digestion.
Calibration standards prepared in IC buffer were processed as per the sample preparation
procedure. Quality control samples at two levels (LQC, HQC) were prepared in IC buffer and
processed as per the sample preparation procedure with varying amount of trypsin. The trypsin
amounts used were 100 ng, 400 ng, 500 ng, 600 ng and 900 ng representing 20, 80, 100, 120 and
180 percent variability in trypsin activity, respectively. Six replicate samples were analyzed at
each trypsin level. The OPN concentrations obtained with 100% trypsin activity were used to
calculate average concentrations at each level. Plots of percent deviation from average
concentrations (100% trypsin activity) versus percent trypsin activity were used to assess the
impact of trypsin variability on precision. The variance was compared using Brown-Forsythe
test.
4.2.8 Evaluation of plasma OPN levels in breast cancer patient and healthy individuals.
Samples from breast cancer patients (n=10) were purchased from Biochemed services and
healthy individual plasma samples (n=10) were randomly chosen from the in-house inventory at
Pharmaceutical Product Development, LLC (PPD), Richmond, USA. These samples were
analyzed with the validated method.
4.3

RESULTS AND DISCUSSION

4.3.1 Method Development
4.3.1.1 Signature Peptide Selection
A tryptic peptide ‘160GDSVVYGLR’ was chosen as the signature peptide after the in-silico
investigations. This amino acid sequence was unique for hOPN from a BLAST search of the
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Homo sapiens genome using UniProtKB/Swiss-Prot. Since this peptide (GDSVVYGLR)
contains functional domains such as the integrin binding site of hOPN (RGDSVVYGLR) and the
sites for proteolytic cleavage by MMPs and CPB-2, this tryptic peptide is a biologically relevant
signature peptide of hOPN.

Figure 4-3: Schematic of the method procedure.
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Additionally, this peptide did not show any post-translational phosphorylation, thus avoided an
additional dephosphorylation step during sample processing. The schematic representation of
method procedure is show in Figure 4-3.
4.3.1.2 Conventional Flow LC-MS/MS Method
Synthetically manufactured signature peptide (GDSVVYGLR) was used for development of LCMS/MS conditions. The mass spectra showed that a peak corresponding to the +2 charge state of
the peptide was the most intense and was used as the precursor ion. The selected precursor ion
was fragmented and the two most intense fragment ions (y4 and y5) were chosen for the method
(see Table 4-1). The signal responses obtained from both SRMs of the signature peptide were
summed in the final quantitation method to achieve lower detection limits.
Column trapping to allow online sample enrichment prior to separation on the analytical column
was used. After initial digestion studies, the gradient conditions of the method were further
modified by varying the gradient steepness to resolve a digestion by-product (GDSVVY) peak
from the signature peptide peak. Evaluation of hOPN calibration standards, prepared in digestion
buffer, showed that the calibration curve was linear over the range of 100 – 1000 pg/mL with a
mean correlation coefficient of 0.9972. A weighting factor of 1/x was used. No internal standard
was used during analysis on this system.
4.3.1.3 Digestion Optimization
Initial digestion studies showed that the time profile plot of the signature peptide concentration
was biphasic indicating that the signature peptide obtained on digestion of hOPN was unstable
(Figure 4-4). Such trends have been observed in other studies involving tryptic digestions
(Agger, et al. 2010, Brownridge, et al. 2011a, Proc, et al. 2010, van den Broek, et al. 2013b). To
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investigate the decrease in peptide concentration over time, the synthetic signature peptide was
incubated with and without trypsin. A decrease in peptide concentration over time was seen
which was not seen with controls that did not contain trypsin. The results indicated that the
signature peptide was being degraded in the presence of trypsin. To determine possible
degradation products, the signature peptide was incubated with trypsin and the digests were
analyzed using LC-MS/MS in the precursor ion scan mode. The probable masses of cleaved
products of the signature peptide were obtained using Protein Prospector software and the
chromatograms were scanned for the presence of these cleaved products. The chromatograms
showed a peak with mass of 693.4 Da corresponding to the cleaved product ‘GDSVVY’. The
authenticity of the peak was verified by conducting a product ion scan. As the cleavage took
place on the carboxy terminal end of tyrosine, it indicated an enzymatic activity similar to
chymotryptic digestion. Trypsin is known to undergo autolysis and may show a chymotrypsinlike activity(Tryspin gold mass spectrometry grade technical bulletin Part # TB309 Revised 03/13). It
was speculated that cleavage of the signature peptide was a result of trypsin autolytic activity. A
SRM method was developed to measure the cleaved product (see Table 4-1). In addition, the
chromatographic gradient was modified to resolve the peaks of the signature peptide and cleaved
product.
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Figure 4-4: Digestion profile of hOPN with varying amount of tryspin.
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Digestion studies with different amount of trypsin showed that the highest signature peptide
yields were obtained between 5-10 hours using 500 ng of trypsin per sample (see Figure 4-4).
The digestion efficiency was found to be around 35-40 %.
4.3.1.4 Immunocapture method optimization
4.3.1.4.1 Order of addition
The signature peptide yields using the Strategy I, II and II are given in Figure 4-5. Adjusted
signature peptide concentrations were obtained after subtracting the average blank plasma
concentrations.
From Figure 4-5, it can be seen that the highest signature peptide yield was obtained when the
samples were processed using Strategy I i.e. when immobilization of the antibody on a solid
support is carried out prior to the immunocapture reaction. A probable reason could be that the
immobilization of the “naked” capture antibody is more efficient compared to that of the
preformed antigen-antibody complex due to steric hindrance. Also, no significant difference in
signature peptide yield was seen between immunocapture incubation carried out for 4 hours and
20 hours for Strategy I. Hence, Strategy I with 4 hour immunocapture incubation was used for
further studies. In the final method, the immobilization time was changed from 4 hours to 2
hours.
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Figure 4-5: Immunocapture optimization studies (Order of addition).
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4.3.1.4.2 Optimization of the amount of Antibody
The result of antibody amount optimization studies is given in Figure 4-6. A ‘hook-effect’ was
seen due to excess coating of monoclonal antibody on the streptavidin coated plates. An
assumption is that overcrowding of the immobilized antibodies results in steric hindrance, thus,
negatively affecting the immuno-complex formation. When more than 0.5 µg of antibody was
used per well, a decline in response was seen followed by response saturation with an increasing
amount of antibody. The final method used 0.5 µg of antibody per well, since the highest
response was obtained at this concentration.
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Figure 4-6: Immunocapture optimization studies (Antibody amount).
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4.3.1.5 Evaluation of internal standards
A peptide ‘GDSVVYGLR*’ having the same sequence as the signature peptide and containing
an arginine labeled with

13

C6 and

15

N4 was used as the SIL-IS peptide. Another peptide

‘TYDGRGDSVV*YGLRSKSKKF’ having the same sequence as the signature peptide along
with additional amino acid chains flanking both terminal ends and containing a valine labeled
with 13C5 and 15N was used as the extended SIL-IS peptide. The amino acid chains flanking the
terminals were chosen from the hOPN sequence. As hypothesized, comparison of the tryptic
digestion time profiles showed that the extended SIL-IS peptide better mimicked hOPN digestion
than the SIL-IS peptide (See Figure 4-7).
The extended SIL peptide and hOPN digestion profiles can be divided into three phases i.e. the
‘formation phase’, the ‘transition phase’ and the ‘degradation phase’. The formation phase
represent the incubation period between 0-5 hours which is dominant in the formation of
signature peptide or SIL signature peptide from the digestion of hOPN and extended SIL peptide,
respectively. The transition phase represent the incubation period between 5-10 hours where
signature peptide formation and degradation processes occur at similar rates. The degradation
phase represents the incubation period beyond 10 hours in which degradation of the signature
peptide is the most dominant phenomenon. In the case of the SIL peptide, only degradation is
occurring.
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Figure 4-7: Comparison of digestion profiles of hOPN and the two internal standards.
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Variability during trypsin digestion can occur due number of reasons including interfering
substances in

complex biological matrix, lot-to-lot variation in trypsin stock solution and

inadequate removal of surfactants or chaotropic agents from prior sample processing steps. This
variability can be tracked by adding an appropriate internal standard (Bronsema, et al. 2013,
Brownridge, et al. 2011a, Proc, et al. 2010, van den Broek, et al. 2013a). In order to assess the
ability of the two internal standards to account for digestion variability, digestion was carried out
in replicate (n=8) at three different OPN concentration levels and three different amounts of
trypsin (100ng, 500 ng and 900 ng). Digestion was stopped at three time intervals (2, 7 and 14
hours) representing the ‘formation phase’, ‘the transition phase’ and ‘the degradation phase’. The
average response of samples digested with 500 ng trypsin was used to calculate the variability
which was expressed as the percent difference from the average. The term ‘inherent digestion
variability’ was used to represent variability at 100 % trypsin activity i.e. using 500 ng of trypsin
per sample, while ‘forced digestion variability’ was used to represent variability seen at 20 and
180 % trypsin activity.
The inherent and forced digestion variability, across the three phases with the two internal
standards, is shown in Figure 4-8 and 4-9, respectively. In these figures, the QC levels 01, 02, 03
represent the 80, 200 and 500 ng/ml of OPN concentrations, respectively. The whiskers of the
box plots seen in these figures represent range and is a measure of the variability seen in the
response. Brown Forsythe test of unequal variance was used to compare the standard deviations
of the percent deviation from average in the individual groups. The statistical results of this test
are available in supporting information (Table 4-3). The standard deviation of the percent
deviation from average can be used as measure of precision i.e. lesser standard deviation values
would represent higher precision and vice-versa.
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From Figure 4-8, one can observe that the inherent digestion variability decreased with increase
in digestion time when SIL-IS was used. For results analyzed with extended SIL-IS, the
precision was least at 7 hours and highest at 14 hours. The high variability at 7 hours could be
attributed to the transition phase wherein there is simultaneous occurrence of signature peptide
formation and degradation. Highest precision was seen at 14 hours primarily because at this time
interval only a single degradation process is dominant. It was seen that there was no significant
difference between the responses obtained using the two internal standards (see Table 4-3). Thus
we can conclude that the use of either internal standard does not have an impact on the inherent
variability. Also, except for QC_02 samples at 2 hours, all the box plot in Figure 4-8 had their
box plot whiskers within ± 20%. This indicates good precision using both internal standards.
From Figure 4-9, it can be observed that the forced digestion variability decreased with
increasing digestion time when SIL-IS was used. However, when extended SIL-IS was used the
variability at 7 hours was higher than 2 and 14 hours. The least variability was seen at 14 hours.
This trend is similar to the inherent trend observed for inherent digestion variability. At each
time interval, the variability decreased with increasing OPN concentration. This was more
prominent for the responses analyzed using SIL-IS.

Also, the variability in the responses

analyzed using SIL-IS was significantly higher (see Table 4-3) in comparison to the response
analyzed using extended SIL-IS, except for QC_03 samples at 7 and 14 hours. It can be seen that
the data points analyzed using SIL-IS are more focused near the interquartile range instead of the
median.
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Figure 4-8: Evaluation of internal standards ability to account for digestion variability
(inherent).
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Figure 4-9: Evaluation of internal standards ability to account for digestion variability
(forced).
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In contrast, the responses analyzed using extended SIL-IS are more focused around the median
indicating that the trypsin activity variation had a smaller impact on the final response. Also, it
can be seen that there is a significant difference in the precision at all-time points except QC-03
samples at 7 and 14 hours (see Table 4-3). Response obtained using extended SIL-IS showed
higher precision in comparison to SIL-IS. Thus we can conclude that the extended SIL peptide
would be a better internal standard when a digestion variability between samples is expected.
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Table 4-3: Results of digestion variability studies using different internals standards
Variability
Type

Time
(Hours)

QC
Level

Extended SIL-IS

SIL-IS

(Std Dev)
10.68
16.29
8.57
12.31
13.22
19.86
4.65
5.81
5.10
21.91
22.65
14.81
17.30
27.30
28.96
14.16
11.22
15.06

(Std Dev)
14.67
19.62
6.51
6.34
13.51
10.52
7.12
5.22
7.77
61.61
65.71
56.98
42.16
40.62
35.46
34.50
26.49
25.24

Inherent
2
1
Inherent
2
2
Inherent
2
3
Inherent
7
1
Inherent
7
2
Inherent
7
3
Inherent
14
1
Inherent
14
2
Inherent
14
3
Forced
2
1
Forced
2
2
Forced
2
3
Forced
7
1
Forced
7
2
Forced
7
3
Forced
14
1
Forced
14
2
Forced
14
3
* p-value < Level of significance α =0.003
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Brown-Forsythe Test
(F Ratio)
0.0040
0.0314
0.9208
2.4068
0.4010
0.4795
0.8653
0.0018
0.5267
87.3208
119.4768
324.2888
120.9018
12.0396
4.5444
65.2119
46.4727
3.6225

(p-value)
0.9502
0.8618
0.3536
0.1431
0.5376
0.5
0.368
0.9665
0.48
<.0001*
<.0001*
<.0001*
<.0001*
0.0016*
0.0413
<.0001*
<.0001*
0.0666

4.3.2 Method Transfer
The initial method used conventional flow HPLC coupled to a Sciex API 4000 Qtrap mass
spectrometer. This method had a lower limit of quantification of 100 pg/ml for the signature
peptide prepared in digestion buffer. The detectability limit of the signature peptide and the low
overall sample processing efficiency of the method (17%) restricted the method range to a lower
limit of 5 ng/ml of hOPN using 500 µL of sample. Biomarker investigations usually have limited
sample availability. This was the primary reason for method transfer to the MFLC-MS/MS
system. In addition, we wanted to evaluate the microflow LC system for regulated quantification
of large molecules. The microflow LC system had a 1226 times higher signal-to-noise ratio as
compared to the conventional flow LC system. This allowed us to lower the sample volumes to
20 uL while achieving similar detection limits. The conventional flow method used streptavidin
coated magnetic beads for immunocapture which were necessary due to the high sample volume.
The low sample volume of the new method allowed the immunocapture to be performed on more
convenient high binding capacity streptavidin coated plates. In addition, the lower detection
limits of the microflow LC system allowed for further sample dilution to avoid matrix
interferences. The use of low flow rates also resulted in a 100-fold reduction in solvent
consumption.
4.3.3 Method Validation Studies
A prime concern during method development was establishment of the method validation range.
As discussed earlier, there is ambiguity in reported absolute concentrations of hOPN in
biologically samples, primarily due to the differences between individual ELISA kits. For this
reason, eights lots of healthy individual plasma lots were randomly chosen from the in-house
inventory at PPD and screened to establish baseline plasma OPN levels. An average
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concentration of 49±17 ng/mL (mean + SD) was obtained from the screened samples. A 4-10
fold increase in OPN levels has been observed in diseased populations relative to healthy
individuals from previous studies involving immunoassays(Rodrigues, et al. 2007). Hence, a
concentration range of 25-600 ng/mL, which includes mean baseline concentration and a 10-fold
increase in baseline concentrations, was chosen for the validation studies.
4.3.3.1 Selectivity and Matrix Effect
A common challenge in biomarker analysis is to select an appropriate matrix in which to prepare
the standard curve. Ideally, this should be free of target analytes and identical to the sample
matrix. To avoid matrix effects between individual lots, each sample was diluted 40-fold prior to
immunocapture. This high dilution allowed use of the IC buffer as a surrogate matrix.
From Figure 4-10, it can be seen that the calibrations curves prepared using plasma standards and
surrogate matrix standards are parallel. The plasma concentrations were not adjusted to account
for baseline levels. The slope of the surrogate matrix i.e. IC buffer curve was 0.00073 (95%
Lower confidence interval = 0.0067 and 95% Upper confidence interval = 0.00078) while the
slope of the plasma curve was 0.00074 (95% Lower confidence interval = 0.0066 and 95%
Upper confidence interval = 0.00081). The overall of 95% confidence interval of both slopes
indicates that the slopes are not significantly different. Hence, we can conclude that any matrix
difference that may exist would not preclude selective quantification provided the samples are
diluted 40-fold prior to immunocapture.
No interfering peak was present at the retention time of an internal standard.

Spike recovery

ranged from -13.1 to 19.2% in all the fortified samples after adjusting for the baseline levels.
Representative chromatograms of the blank samples prepared in buffer and plasma are given in
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Figure 4-11 and 4-12, respectively. Representative chromatograms of LLOQ standard prepared
in buffer and plasma are given in Figure 4-13 and 4-14, respectively.

Figure 4-10 : Parallelism experiment to demonstrate the suitability of the surrogate matrix i.e.
IC buffer.

103

Figure 4-11: Representative chromatogram of blank (IC buffer) with SIL-IS.
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Figure 4-12: Representative chromatogram of blank (IC buffer) with extended SIL-IS.
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Figure 4-13: Representative chromatogram of LLOQ standard (IC buffer).
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Figure 4-14: Representative chromatogram of LLOQ QC (plasma).
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4.3.3.2 Linearity
The standard curves demonstrated a linear response over the concentration range of 25-600
ng/mL. The calibration curves yielded a mean (n=3) correlation coefficient of 0.9967. The
percent deviation from nominal (%DFN) for the mean back-calculated values of the calibration
standards were between -2.16% and 3.69%. Precision of the calibration standards measured as
the percent relative standard deviation for the mean back-calculated values ranged from 2.98% to
9.59%.
4.3.3.3 Accuracy and Precision
The limit of quantification (LLOQ) was established at 25 ng/mL and demonstrated a precision of
10.7 % and 5.93 % in surrogate matrix and in plasma, respectively. The LLOQ demonstrated
accuracy of -12.0 % and -1.21 % in surrogate matrix and in plasma, respectively. Intra-assay
results of accuracy and precision for quality control samples using SIL-IS and extended SIL-IS
are shown in Table 4-4 and 4-5. Inter-assay results of accuracy and precision for quality control
samples using SIL-IS and extended SIL-IS are shown in Table 4-6 and 4-7. One LQC sample
was excluded from statistically analysis citing sample processing error as demonstrated by low
internal standard peak response.

Intra-assay and inter-assay precision with both internal

standards was within 15%. No substantial advantage was seen in accuracy or precision with the
use of extended peptide. Dilution integrity was established by analyzing ‘over-the-curve’ QC
after a 2-fold and 4–fold dilution. The back calculated concentrations after analyzing DI QC
samples post 2-fold and 4-fold dilutions yielded an accuracy of -11.83% and -7.60%,
respectively and a precision of 6.97% and 5.04%, respectively.
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Table 4-4: Intra-day accuracy and precision (SIL-IS)
IC Buffer

Plasma

Matrix
LQC

MQC

HQC

LQC

MQC

HQC

Nominal concentration
(ng/ml)

101.0

236.0

550.0

137.0

271.0

584.0

Mean calculated
concentration (ng/ml)

99.3

230.0

568.7

127.8

253.8

540.3

Standard deviation

7.52

8.02

38.28

10.25

22.27

25.65

Percent coefficient of
variation

7.57

3.49

6.73

8.02

8.77

4.75

Percent deviation from
nominal concentration

-1.67

-2.54

3.39

-6.70

-6.33

-7.49
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Table 4-5: Intra-day accuracy and precision (extended SIL-IS)
IC Buffer

Plasma

Matrix
LQC

MQC

HQC

LQC

MQC

HQC

Nominal concentration
(ng/ml)

101.0

236.0

550.0

137.0

271.0

584.0

Mean calculated
concentration (ng/ml)

99.7

222.3

569.3

130.8

249.9

560.8

Standard deviation

9.03

8.43

35.90

10.88

16.16

25.22

Percent coefficient of
variation

9.06

3.79

6.31

8.32

6.47

4.50

Percent deviation from
nominal concentration

-1.29

-5.83

3.52

-4.51

-7.78

-3.97
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Table 4-6: Inter-day accuracy and precision (SIL-IS)
IC Buffer

Plasma

Matrix
LQC

MQC

HQC

LQC

MQC

HQC

Nominal concentration
(ng/ml)

101.0

236.0

550.0

137.0

271.0

584.0

Mean calculated
concentration (ng/ml)

101.0

235.0

574.0

123.0

254.0

524.0

Standard deviation

6.78

12.8

33.9

22

23.2

42.9

Percent coefficient of
variation

6.75

5.45

5.9

17.9

9.13

8.19

Percent deviation from
nominal concentration

-0.47

-0.31

4.43

-10.00

-6.28

-10.30
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Table 4-7: Inter-day accuracy and precision (extended SIL-IS).
IC Buffer

Plasma

Matrix
LQC

MQC

HQC

LQC

MQC

HQC

Nominal concentration
(ng/ml)

101.0

236.0

550.0

137.0

271.0

584.0

Mean calculated
concentration (ng/ml)

103.0

234.0

580.0

130.2

254.0

542.0

Standard deviation

8.98

21.2

38

10.50

21.4

41.4

Percent coefficient of
variation

8.72

9.06

6.56

8.06

8.43

7.65

Percent deviation from
nominal concentration

1.92

-0.57

5.43

-4.94

-6.38

-7.25
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4.3.3.4 Stability Studies
The stock solution was stored at -80°C after reconstitution in phosphate buffered saline and it
was stated to be stable for 3 months in those storage conditions as per supplier instructions. The
plasma QC samples were found to be stable after 4-freeze thaw cycles. Short term stability was
assessed for 18 days at -80°C and was found to be within specifications both matrices i.e. IC
buffer and plasma. Samples thawed on the bench were found to be stable for 24 hours both
matrices. Extracted samples from both matrices were found to be stable when stored at stored at
2-8°C for 9 days. The stability studies results are given in Table 4-8.

113

Table 4-8: Results of Stability studies.
Study

Matrix

Freeze thaw Stability
(4 cycles)

Plasma

Short Term Storage
Stability (-80 °C)
(18 days)

IC Buffer

Plasma

IC Buffer
Thawed Matrix Stability
(24 Hours)
Plasma

IC Buffer
Extracted Sample Stability
(2-8 °C)
(9 Days)
Plasma
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Level

N

% DFN

%CV

LQC

6

19.08

4.13

HQC

6

9.45

4.12

LQC

6

15.78

3.18

HQC

6

18.08

5.07

LQC

6

17.34

3.01

HQC

6

6.62

3.42

LQC

6

16.00

3.60

HQC

6

10.53

4.56

LQC

6

14.02

4.34

HQC

6

9.21

2.13

LQC

6

-0.49

3.60

HQC

6

5.84

2.55

LQC

5

-2.38

2.54

HQC

6

-9.78

6.09

4.3.3.5 Evaluation of internal standards ability to account for digestion variability in the
final method
Ideally an internal standard's ability to account for variability is measured in controlled settings.
As seen earlier precision and accuracy studies showed that there was no significant difference in
precision or accuracy when either internal standard peptide was used. However, from initial
experiments, we had seen that the extended SIL-IS peptide should be a better internal standard to
account for variability in trypsin activity. The impact of trypsin variability on precision was
assessed from the slopes of plots of percent deviation from the average assayed concentration (at
100% trypsin activity) versus percent trypsin activity. A lower value for the slope would indicate
that there is better precision and that the trypsin variability is lessened by the presence of the
internal standard.
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Figure 4-15 : Plots of the percent deviation from average concentrations (100% trypsin
activity) versus percent trypsin activity.
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From Figure 4-15, it can be seen that use of the SIL peptide as an internal standard resulted in
slopes of 0.418 and 0.567, obtained for LQC and HQC s, respectively. Alternatively, when the
extended SIL peptide was used as the internal standard, plots were obtained with slopes of 0.031
and 0.136 for LQC and HQC s, respectively. This suggests that during analysis of unknown
samples, if a particular sample has diminished or enhanced trypsin activity, the impact of this on
results would be less when using an extended SIL peptide as an internal standard.
4.3.4 Evaluation of plasma OPN levels in breast cancer patient and healthy individuals.
An average OPN concentration of 55.4±15.3 ng/mL was determined in the plasma samples of
healthy volunteers (see Figure 4-16). Plasma OPN concentrations in breast cancer patients were
elevated and ranged from 85-637 ng/mL. In particular, 30% of the samples (n=10) showed more
than 9-fold increase over the mean plasma concentrations in healthy volunteers. As OPN plays
an important role in cancer progression (Rodrigues, et al. 2007), a probable speculation is that
these plasma samples were from patients with advanced disease. Since these plasma samples
were purchased from a commercial source, this could not be confirmed due to the lack of
availability of additional disease information on these patients.
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Figure 4-16: Comparison of plasma OPN levels in healthy individuals and breast cancer
patients.
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4.4

CONCLUSION

We developed and validated a method for quantification of human osteopontin from plasma
using a capillary microflow LC-MS/MS system. The use of microflow LC-MS/MS platform
resulted in 1226 times increase in signal-to-noise ratio, which in turn, allowed the use of lower
sample volumes and reduced solvent consumption. This method demonstrated applicability of
Waters iKey/MS™ separation device for regulated analysis of proteins.
The quantification was carried out by using a biologically relevant signature peptide
GDSVVYGLR that was obtained after tryptic digestion of immunocaptured OPN. Validation
was carried out using IC buffer as a surrogate matrix. A 40-fold dilution, prior to
immunocapture, enabled avoidance of matrix effects. The method was accurate, precise and
demonstrated good linearity over the range of 25-600 ng/mL. Stability studies demonstrated
good bench-top, post preparative, freeze thaw and storage stability.
The selected signature peptide showed an additional chymotrypsin-like cleavage during digestion
resulting in degradation of the peptide. In order to ensure that any variability that could arise
from the two processes of peptide formation and degradation occurring simultaneously, internal
standardization prior to digestion was incorporated in the method. A SIL peptide and an
extended SIL peptide were evaluated as internal standards. Validation studies showed that under
controlled conditions and long digestion time there was no significant difference in precision
when either of the internal standards as used. However, when trypsin activity was forcibly
varied, the extended SIL peptide was found to give better precision. This difference was more
pronounced at when digestion was carried out at shorter time intervals.
The applicability of the method for measuring plasma OPN levels was demonstrated by
analyzing samples obtained from breast cancer patients and healthy individuals. Breast cancer
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patient samples demonstrated elevated plasma OPN concentrations. The method range covers
both healthy as well as diseased population plasma OPN concentrations. Human osteopontin can
undergoes post-translational proteolytic cleavage which can interfere in its quantification in
ligand binding assays. Considering its use as a biomarker, this method ensures that the captured
hOPN is biologically active by using a biologically relevant signature peptide. Thus, this method
is proposed as an alternative to ELISA and for measuring plasma OPN concentrations during
oncological screening and monitoring.
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CHAPTER 5

5

DEVELOPMENT OF AN IN-VITRO CELL BASED SYSTEM FOR EVALUATION
OF TOBACCO PRODUCTS FOR CARDIOVASCULAR RISK BY MEASURING
THE SECRETED OSTEOPONTIN LEVELS IN TOBACCO EXTRACT EXPOSED
ENDOTHELIAL CELLS

5.1

INTRODUCTION

Mass spectrometry based methods show great promise as an alternative to immunoassays for
quantification of protein biomarkers (Makawita, et al. 2010, Ramanathan, et al. 2011, Rauh
2012). Mass spectrometry provides a universal platform for selective analysis of biomarker
proteins. In particular, a mass spectrometer has the ability to differentiate between a biomarker
protein and its post-transnationally modified form (Makawita, et al. 2010, Wang, et al. 2009). In
this chapter, our objective was to develop a mass spectrometry based method to simultaneously
measure secreted human osteopontin and its matrix metalloproteinase-3 (MMP-3) cleaved Nterminal fragment and to use this method to develop an in-vitro cell-based system to evaluate
tobacco products for cardiovascular risk.
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The tobacco plant has been smoked, chewed, or inhaled for many centuries (Willis, et al. 2012).
Smoked tobacco, mainly cigarettes, has been the predominant form of tobacco use. In the US,
smokeless tobacco (ST) has gained tremendous popularity in last few decades (Delnevo, et al.
2014). This popularity can be attributed to a number of factors, including an unsupported
perception of safety; apparent health advantages of ST use over smoked tobacco; increased
smoke-free laws across the country; the ease of use in a concealed manner; and a substitute
product for smoking cessation (Piano, et al. 2010).
Many forms of ST products exist worldwide such as snus, snuff, chewing tobacco, gutka, pan
and mishri. In the United States, the predominant forms of ST products are chewing tobacco and
snuff (Delnevo, et al. 2014, Willis, et al. 2012).Chewing tobacco is available as loose leaves,
plugs (bricks), or twists of rope and is placed between the cheek and lower lip, typically toward
the back of the mouth (Willis, et al. 2012). It is either chewed or held in place. Snuff is finely cut
or powdered tobacco. It is packaged moist or dry; most American snuff is moist (also referred to
as snus). It is available loose, in dissolvable lozenges or strips, or in small pouches similar to tea
bags. A pinch or pouch of moist snuff is placed between the cheek and gums or behind the upper
or lower lip (Willis, et al. 2012).
Cigarette smoking has been associated with a number of harmful effects including an increased
risk for cancer, cardiovascular diseases, chronic obstructive pulmonary disease and asthma .
Cigarette smoking is known to promote atherosclerosis mainly through pathological processes
such as endothelial dysfunction, inflammation and thrombosis (Unverdorben, et al. 2009,
Winkelmann, et al. 2009). Presently, there is not a full understanding of the mechanisms
underlying the susceptibility of tobacco users to cardiovascular disease which is due in part to a
lack of knowledge about all the constituents present in tobacco products (Bishop, et al. 2012).
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Also, there is a lack of standardized in vitro testing systems for tobacco products (Johnson, et al.
2009).
A recent study showed that non-cytotoxic concentrations of cigarette smoke particulate matter
increased osteopontin levels in cultured human endothelial cells (Bishop, et al. 2012). This effect
was reduced in the presence of ascorbate, thus these researchers associated smoking particulate
matter exposure to increased oxidative stress. In addition, a particulate matter concentration
dependent rise in matrix MMP-3 was observed in these experiments. As osteopontin is known to
be cleaved by MMP-3 to form a bioactive fragment (Agnihotri, et al. 2001), thus, a potential role
of the osteopontin fragment is implicated. Also, the study showed that serum osteopontin levels
were significantly lowered as compared to those measured prior to smoking cessation in smokers
who quit smoking for 5 days, thus showing an agreement with the conclusion of the cell
exposure studies (Bishop, et al. 2012).
Currently, there is no standard ELISA for measuring OPN, which has been the major limitation
for clinical development of OPN as a biomarker in cancer. In fact, studies have shown that OPN
blood concentrations measured with different ELISAs gave different absolute values ranging
from nanogram per milliliter to milligram per milliliter (Anborgh, et al. 2009, Blum, et al. 2012,
Plumer, et al. 2008). In addition, western blot is the only way to measure MMP-3 cleaved
osteopontin fragments. Western blot methods are semi-quantitative and have issues with
antibody cross-reactivity. Hence, there is a need for development of a quantitative method that
can simultaneously measure osteopontin and osteopontin fragments (thrombin and/or MMP
cleaved products) from a biological matrix. One of the objectives of this chapter was to develop
a method to simultaneously measure secreted human osteopontin and its MMP-3 cleaved Nterminal fragment from supernatants of endothelial cells.
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Considering osteopontin as a biomarker of endothelial dysfunction (Scatena, et al. 2007,
Shimada, et al. 2005, Waller, et al. 2010), we hypothesized that a cell based system as described
by Bishop et al, could be used to assess the cardiovascular risk. A specific objective of this
chapter, was to develop a cell based in vitro system for evaluation of tobacco products for
cardiovascular risk toxicity studies related to tobacco regulation. An immortalized human
umbilical vascular endothelial cell line i.e. EA.hy926, was used to avoid variability arising due to
use of primary cells. The study objective was to measure and correlate levels of secreted
osteopontin and the MMP-3 cleaved N-terminal osteopontin fragment from the cell based system
upon tobacco product exposure. A significantly high level of osteopontin in comparison to nonexposed controls would indicate endothelial dysfunction.
In our preliminary investigations, digestion studies of human osteopontin showed an interfering
peak in the chromatogram of the MMP-3 cleaved N-terminal fragment of human osteopontin.
Thus, we concluded the LC-MS/MS method, using signature peptides obtained from the
biologically relevant zone i.e. ‘RGDSVVYGLR’, would not be able to distinguish between full
human osteopontin and MMP-3 cleaved N-terminal fragment of human osteopontin.
Additionally, EA.hy926 cells were exposed to cigarette smoke extract and its supernatant was
evaluated for secreted osteopontin levels. It was observed that the secreted osteopontin
concentration in supernatant of cell culture studies were below detection limits. Since the
preliminary results did not indicate that this research objective could be addressed with the
proposed system, this study was terminated.
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5.2

MATERIALS AND METHODS

5.2.1 Reference Materials
Recombinant hOPN was purchased from R&D Systems (Minneapolis, MN, USA). Signature
peptides having the amino acid sequence ‘GDSVVYGLR’ and ‘GDSVVYG’ for hOPN and the
MMP-3 cleaved N-terminal hOPN fragment, respectively, were synthesized by Elim
Biopharmaceuticals (Hayward, CA, USA). A stable isotope labeled (SIL) peptide having the
sequence ‘GDSVVYGLR*’, containing an arginine residue labeled with

13

C and

15

N4 was

synthesized by Thermo Scientific (Rockford, IL, USA) and used as the SIL-IS. The labeled
arginine residue resulted in a mass shift of 10 amu from the mass of the OPN-SP. In this chapter,
we will refer to the full OPN signature peptide (GDSVVYGLR) and to the MMP-3 cleaved Nterminal hOPN fragment signature peptide (GDSVVYG) as ‘OPN-SP’ and ‘OPN-SP-1’,
respectively.
5.2.2 Reagents and Chemicals
Cigarette smoke concentrate was purchased from Murthy Pharmaceuticals (Lexington, KY,
USA). Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine serum (FBS), trypsin EDTA
solution (1x), Dulbecco's phosphate buffered saline (D-PBS) and EA.hy926 cells were purchased
from American Type Culture Collection (ATCC). Protease inhibitor cocktail tablets were
obtained from Roche (Indianapolis, IN, USA). HPLC grade water with 0.1% formic acid and
acetonitrile with 0.1% formic acid were purchased from Honeywell Burdick & Jackson
(Muskegon, MI, USA). High grade water was obtained using a Milli-Q integral water
purification system (Billerica, MA, USA). Formic acid, methanol, Trizma hydrochloride (1M),
bovine serum albumin and tween 20 were purchased from Sigma-Aldrich (Saint Louis, MO,
USA). Glacial acetic acid was obtained from Macron Fine Chemicals (Center Valley, PA, USA).
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Sodium chloride solution (5 M) and EDTA solution (0.5M) were obtained from Ambion (Foster
City CA, USA). Trypsin Gold was obtained from Promega (Madison, WI, USA). Biotinylated
antibodies specific to hOPN (MAB193P) were obtained as a gift from Maine Biotechnology
Services (Portland, Maine, USA).

Immuno-capture (IC) buffer and IC wash buffer were

prepared in-house and were comprised of 0.1/ 5.0/ 3.0 /0.2 /91.7 /0.1(v//v/v/v/w) Tween 20/
Trizma

HCl

(1M)/

NaCl

(5M)/EDTA

(0.5M)/water/

bovine

serum

albumin

and

5.0/3.0/0.2/91.8/0.1 (v/v/v/v) Trizma HCl (1M)/ NaCl (5M)/ EDTA (0.5M)/ water, respectively.
Digestion solution, containing of 500 ng/100 µL of trypsin gold, 0.05 pg/100 µL of SIL-IS
peptide and 0.68 pg/100 µL of extended SIL-IS peptide in 50 mM ammonium bicarbonate
buffer, was freshly prepared prior to digestion for the validation studies.
5.2.3 LC-MS/MS method
The LC-MS/MS system consisted of a Waters NanoAcquity UPLC system coupled to at Waters
TQ-S mass spectrometer fitted with an ion key/MS™ separation device. The separation device
consisted of a compact cartridge with an in-built capillary column having an internal diameter of
150 µm and packed with 1.7 µm particles. HPLC grade water with 0.1% formic acid and
acetonitrile with 0.1% formic acid were used as mobile phase A1 and B1, respectively. The LC
system was operated in the trap mode using a single pump system. A Symmetry C18 Guard
Column, 300 µm x 50 mm from Waters (Milford, USA) was used as the trap column. Trapping
was carried out for 2 minutes at a flow rate of 20 µL/min using 99.5% mobile phase A1.
Analytical separation was performed on a Waters BEH 130 C18 iKey™ Separation Device
(100 mm x 150 μm I.D., 1.7 μm). Gradient conditions were as follows: 0.0–0.5 min, isocratic 5%
B1; 0.5 –3.0 min, linear from 5% to 20% B; 3.0 –5 min, linear from 20% to 30% B; 5.0 –7.0
min, linear from 30% to 95% B; 7.0 –8.4 min, isocratic 95% B; 8.4 –8.5 min, linear from 95% to
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5%; 8.4 –8.5 min, isocratic 5% B. The total running time was 9 min and the injection volume
was 20 µL in the full loop mode. The initial flow rate from 0.0 to 0.5 min was kept at 0.5 μL/min
to avoid high back pressure during switch over from trapping to analysis mode. From 0.5 to 8.5
minutes, the chromatographic separation was carried out at a flow rate of 2.5 μL/min. The flow
rate was changed to 1.0 μL/min after 8.5 min. The cone voltage and collision energy were
optimized for each compound using automatic tuning (Intellistart system) in the TQ-S. The
parameters for each compound are listed in Table5-1. The capillary voltage was 3.6 kV, the
source temperature was 100 °C, the source offset was 60 V, and the collision gas was argon.
Dwell times for all transitions were 0.044s.
5.2.4

Sample Preparation

Biotinylated anti-hOPN monoclonal antibodies (1 mg/ well) were immobilized on high capacity
streptavidin coated 96 well plates (Thermo scientific, USA). Samples were diluted 4-fold with IC
buffer and 100 µL of the diluted sample were added to each well. Immunocapture was carried
out at room temperature for 4 hours using a constant vortex of 450 rpm. After 4 hours, the plates
were washed 3 times with immunocapture wash buffer. Digestion was carried out by adding 100
µL of digestion solution to each well and incubating the plates at 37°C in a water bath for 14
hours. Digestion was terminated by adding 2 µL formic acid to each well. The digested samples
were transferred a Protein LoBind 96 well plate and analyzed using LC-MS/MS.
5.2.5 Digestion Studies
Mass spectrometric parameters for OPN-SP1 were determined using a Waters Intellistart system.
The retention time for this peptide was determined using the chromatographic method developed
in chapter 4. Human osteopontin stock solution was spiked in 50 mM ammonium bicarbonate
solution to obtain OPN standard solution having concentrations of 39.1, 78.1, 156.3, 312.5.625,
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1250 and 2500 ng/mL.

A 500 uL aliquot of the OPN standard solution was incubated with 200

ng of MMP-3 in a 2 ml Lobind Eppendorf centrifuge tube for 3 hours at 37 °C. The reaction is
terminated by heating at 95 °C for 15 minutes. These samples were then digested with 500 ng of
trypsin at for 14 hours at 37 °C along with controls that were not treated with MMP-3. The
digestion was terminated by adding 10 uL formic acid. The samples were then transferred to an
autosampler plate and analysed by LC-MS/MS.
5.2.6 Cigarette Smoke Extract Exposure studies
5.2.6.1 Method modifications
Human osteopontin standard solutions (100 and 500 ng/mL) were prepared by spiking
recombinant hOPN in IC buffer or DMEM media, with and without complete protease inhibitor,
from cell culture flasks used for sub-culturing the EA.hy926 cells. The standards were analyzed
for the amount of human osteopontin using GDSVVYGLR as the signature peptide using the
LC-MS/MS method. A modified method that was developed in Chapter 4 was used. The
modification included a 4-fold dilution of the samples prior to immunocapture instead of a 40fold dilution. The method was evaluated for capture differences between the DMEM media (with
and without complete protease inhibitor) and IC buffer.
5.2.6.2 Exposure studies
Immortalized human umbilical vein endothelial cells (EA.hy926 cells) were cultured in DMEM
and fetal bovine serum (10%). The plates were incubated in at 37°C in a 5% CO2 humidified
atmosphere. Cells were seeded at 1×105 cells/well to allow approximately 80% confluence at the
time of media harvest, after all exposure studies. Cigarette smoke extract (CSE) containing
40mg/ml particulate matter and 1.7 mg nicotine was purchased from a commercial vendor and
diluted with DMEM + 10% FBS.
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Cells were treated for 24hr either with cigarette smoke extract or nicotine or with 0.5% DMSO
as a diluent control. In all exposure studies, the concentrations used of particulate matter was 20,
40, 60 and 100 µg/ml, and concentration used of nicotine was 0.85, 1.7, 2.6 and 4.25 µg/ml in
the exposure studies. After 24 hours, the media from the plates was aliquoted into a 1.5 ml
Lobind Eppendorf centrifuge tube containing complete EDTA-free protease inhibitor cocktail.
The samples were processed as per sample preparation procedure and analyzed using LCMS/MS along with hOPN standards (8-500 ng/ml).
5.3

RESULTS AND DISCUSSION

Mass spectrometric parameters obtained during tuning of the OPN-SP1 are given in Table 5-1.
The b5 fragment ion (m/z 458.31) had the highest intensity and its mass transition was included
in method developed in Chapter 4. Chromatographic evaluation of the synthetic signature
peptide using the LC-MS/MS method developed in Chapter 4 showed a peak at the retention
time of 4.6 mins.
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Table 5-1: Mass spectrometric Parameters of GDSVVYG
Parent m/z

Cone
Voltage

Daughters

Collision
Energy

1

696.67

50

458.31

18

2

696.67

50

72.04

50

3

696.67

50

136.03

50

4

696.67

50

341.22

28

Compound

GDSVVYG
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5.3.1 Digestion Studies
OPN digestion study results with MMP-3 and trypsin are given Table 5-2. It can be seen that
OPN digestion with MMP-3 and trypsin resulted in the formation of GDSVVY. A linear
increase in the peak area of the GDSVVYG peptide was seen in the digestion carried out with
MMP3 and Trypsin. Digest fragments increased with an increasing amount of OPN as seen
Figure 5-1. However, when OPN was digested only with trypsin, small amount of GDSVVYG
peptide were obtained as see in Table 5-2. This unexpected GDSVVYG peptide formation
during trypsin digestion would interfere in the simultaneous quantitative estimation of full hOPN
and MMP-3 cleaved N-terminal fragment of hOPN.
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Table 5-2: Evaluation of the GDSVVYG fragment from OPN digest samples
Average OPN-SP2 (GDSVVYG)

Peak

Area (cps)
OPN Concentration (ng/ml)
Trypsin Digestion

MMP-3 + Trypsin Digestion

(n=2)

(n=3)

39.1

850

2858

78.1

2299

3465

156.3

1335

2506

312.5

1312

5345

625.0

1087

8133

1250.0

2918

9494

2500.0

3092

16051
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Average Peak Area of GDSVVYG
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Figure 5-1: GDSVVYG formation upon digestion of hOPN with MMP-3 and trypsin
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5.3.2 Cigarette smoke extract exposure studies
The method developed in chapter 4 was modified for the immunocapture step to accommodate
changes in the sample matrix i.e. DMEM cell media and to increase the amount
immunocaptured. The method developed in chapter 4 was modified for the immunocapture step
wherein a 4-fold dilution of the sample was carried out prior to immunocapture instead of a 40fold dilution. This modification in the method enabled higher amount of immunocaptured
protein. From Figure 5-2, it can be observed that there was no significant difference in the
immunocaptured hOPN amount between the hOPN standards prepared in IC buffer and DMEM
buffer. This modified procedure was used for analyzing samples obtained in the cigarette extract
exposure studies in EA.hy926 cells.
The study conducted by Bishop et al, used HUVECs to demonstrate secretion of hOPN upon
exposure to cigarette smoke particulate matter. HUVECs are primary cells and have an average
life span of 10 serial passages and can be kept in culture for maximum of 5 months (BouÃ¯s, et
al. 2001). We wanted a more rugged immortalized cell based system that could be routinely used
in different laboratories ensuring good reproducibility. In order to improve reproducibility and
life span in culture, we chose an immortalized HUVEC cell line i.e. EA.hy926 cells for this
study. EA.hy926 are obtained from a fusion of HUVEC and lung carcinoma cell A549 and it is
the most widely used immortalized HUVECs (BouÃ¯s, et al. 2001).
In the study conducted by Bishop et al, HUVECs were exposed for 24 hours to cigarette smoke
particulate matter and this resulted in a dose dependent increase in the concentration of secreted
osteopontin in the media (Bishop, et al. 2012). In our study, the cigarette smoke extract was
obtained from a commercial source. The extract was certified to contain 40 mg/ml of particulate
matter and 1.7 mg/ml of nicotine. The cigarette smoke extract was obtained by smoking
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University of Kentucky's 3R4F Standard Research Cigarettes on an FTC Smoke Machine.
Nicotine exposure in human-derived osteoblast-like cells, aortic vascular smooth muscle cells
and human pancreatic ductal adenocarcinoma cells have shown an increase in osteopontin levels
(Chipitsyna, et al. 2009, Walker, et al. 2001, Wang, et al. 2012b). We wanted to investigate
whether or not nicotine alone had an impact on the osteopontin levels in our study. Hence, in our
investigation, cells were treated with nicotine controls at concentrations similar to those seen in
the cigarette smoke extract.
The media from the exposure study was evaluated using the modified immunocapture method
described earlier along with calibration standards which were prepared by spiking recombinant
hOPN in IC buffer. In the study conducted by Bishop et Al., the study showed an average
concentration of 14 ng/ml in the DMSO controls. Expecting similar hOPN concentrations,
hOPN calibration standards having a concentration range of 8-500 ng/ml were used during the
analysis of the exposure study samples. The osteopontin levels were found to be below detection
limits in all the samples in the exposure study including the DMSO controls. The study was
repeated again with the same particulate matter concentrations for 48 hours. However, the
osteopontin levels in all samples were still found to be below the detection limit. A possible
reason could be that EA.hy926 cells secreted osteopontin at concentrations much lower than
those seen in the HUVEC exposure studies. Variability in the detected hOPN concentrations
between different commercially available immunoassay kits has been reported. Thus, another
reason could be that the absolute hOPN levels in the HUVEC study may be inaccurate i.e.
overestimated.
As the exposure studies did not yield measurable osteopontin levels in the cell media, it would be
very challenging to use this cell line for development of the in-vitro cell based system for routine
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screening of tobacco products. Since the preliminary results did not indicate that this research
objective could be addressed with the proposed system, this study was terminated.

Response Ratio ( Anlyte Peak Area/IS Peak
Area)
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Figure 5-2: Evaluation of matrix on hOPN immunocapture

136

DMEM+ PI
(500 ng/ml)

5.4

CONCLUSION

In 2009, the US Congress passed the Family Smoking Prevention and Tobacco Control Act
mandating regulation of the tobacco industry by the Food and Drug Administration (FDA)
through the FDA Center for Tobacco Products (CTP) (Prevention 2009). Since then there has
been an increase in the need for in-vitro tools for regulating tobacco products (Hecht 2012,
Leischow, et al. 2012). Based on the findings of Bishop et al., we proposed an in-vitro cell based
system to evaluate tobacco products for cardiovascular risk. The primary objective of this system
was to simultaneously measure secreted osteopontin and the MMP-3 cleaved N-terminal
osteopontin fragment using LC-MS/MS from media of cells exposed to tobacco product extracts.
However, our preliminary studies indicated that our proposed LC-MS/MS strategy would not be
able to simultaneously measure full hOPN and its MMP-3 cleaved fragment due to an
unexpected interference seen at the retention time of signature peptide for the MMP-3 cleaved
fragment of hOPN. In addition, our initial tobacco extract exposure studies in an immortalized
endothelial cell line did not yield detectable osteopontin levels. Since the preliminary results did
not indicate that this research objective could be addressed with the proposed system, this study
was terminated.
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CHAPTER 6

6

AN EXTENDED STABLE ISOTOPE LABELED SIGNATURE PEPTIDE
INTERNAL STANDARD FOR TRACKING IMMUNOCAPTURE OF HUMAN
OSTEOPONTIN FOR LC-MS/MS QUANTIFICATION

Drawn from manuscript submitted to Biomedical Chromatography., August 2014

6.1

INTRODUCTION

Internal standardization is an important aspect of the method development process for mass
spectrometry based quantification of proteins. Various internal standardization strategies for
mass spectrometry based protein quantification have been proposed previously and reported in
several review articles (Bronsema, et al. 2012, Brun, et al. 2007, Pailleux, et al. 2012, van den
Broek, et al. 2013a). Ideally internal standards should compensate for all variations encountered
during sample processing as well as instrumental response fluctuations. Sample processing steps
usually involve a protein purification step and an enzymatic digestion step. The most commonly
used internal standard for protein quantification is a stable isotope labeled (SIL) form of the
signature peptide, commonly referred to as the SIL-IS peptide. A SIL-IS peptide contains amino
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acids labeled with the stable isotopes of

13

C or

15

N thus it is physiochemically identical to the

signature peptide but can be easily differentiated on the mass analyzer due to the mass difference
imparted by the presence of the isotope. The major advantage of using a SIL-peptide is that these
can be synthetized at relatively low cost. A SIL-peptide IS is usually added before enzymatic
digestion and can efficiently compensate for extraction recovery, peptide instability and LCMS/MS variability. However, they do not account for proteolytic digestion variability or any
variation in the protein purification processes (Brun, et al. 2009, Li, et al. 2012).
A cost effective internal standardization variability in digestion efficiency is achieved by using
extended SIL-IS peptides. An extended SIL-peptide, i.e. a SIL-IS peptide having cleavable
groups flanking either side of side of a SIL-peptide, is added prior to digestion and these have
shown to compensate for variability in digestion efficiency in addition to extraction recovery,
peptide instability and LC-MS/MS instrumental variability. (Barnidge, et al. 2004, Neubert, et
al. 2013, Ocana, et al. 2010).
In order to compensate for variability arising during protein purification, a SIL-IS protein may be
required. SIL-proteins can be obtained by incorporating stable isotope labeled amino acids into
the target protein (Ong 2002, Picard, et al. 2012). This can be achieved using metabolic labeling
by incubating cells in a medium containing stable isotope labeled amino acids popularly known
as Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) (Ong 2002). Alternatively,
SIL-proteins can also be made by in vitro protein synthesis in a cell free system or can be
chemically synthesized if it a small protein (Jian, et al. 2013). SIL-protein standards may be
ideal internal standards for protein quantifications as they can compensate for immunoaffinity
isolation variability, enzymatic digestion variability, extraction recovery, peptide instability and
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LC-MS/MS variability. However, a major drawback of SIL proteins is a lack of commercial
availability and high cost.
Human osteopontin (hOPN) is a secreted biomarker protein which is present in various
biological fluids including blood, milk and urine (Lund, et al. 2009). It is implicated in a variety
of disease states, including cardiovascular disorders, cancer, and several chronic inflammatory
diseases (Lund, et al. 2009, Rodrigues, et al. 2007, Waller, et al. 2010). In our previous work, we
developed and validated an immunoaffinity coupled liquid chromatography tandem mass
spectrometry (LC-MS/MS) method to quantify human osteopontin from plasma using a
biologically relevant signature peptide GDSVVYGLR (Faria, et al.). We also demonstrated the
advantages of using an extended stable isotope labeled (SIL) signature peptide as an internal
standard (IS) to compensate for digestion variability. In that method however, the internal
standardization did not compensate for immunocapture variability as internal standard was added
post immunocapture.
We hypothesized that an extended SIL-IS peptide could be used to compensate for
immunocapture variability during protein quantification provided that immunocapture is carried
out with an antibody that binds to a common epitope present on both the protein and SIL-IS
peptide. This hypothesis is based on the assumption that any change in immunocapture
efficiency should impact analyte protein and IS peptide binding proportionally. In a proof of
concept investigation, we demonstrated the ability of an extended SIL-IS peptide to compensate
for immunocapture variability using a hOPN specific antibody (MAB222P) that has an epitope
in the signature peptide region (DSVVYG) of the protein. A schematic of the quantification
strategy is shown in Figure 6-1.
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Figure 6-1: Strategy for human osteopontin qunatification using an antibody selective for the
signature peptide
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6.2

EXPERIMENTAL

6.2.1 Reagents and Chemicals
Recombinant hOPN (rhOPN) was purchased from R&D Systems (Minneapolis, MN, USA). The
OPN signature peptide (OPN-SP), with an amino acid sequence ‘GDSVVYGLR’, was
synthesized by Elim Biopharmaceuticals (Hayward, CA, USA). An extended SIL peptide
(TYDGRGDSVV*YGLRSKSKKF) and a SIL peptide (GDSVVYGLR*), obtained from
Thermo Scientific (Rockford, IL, USA), were used as the IS peptide I and IS peptide II,
respectively. The IS peptide I upon cleavage by trypsin yielded GDSVV*YGLR. The labeled
amino acids V* and R* had additional mass of 6 and 10 Da, respectively. HPLC grade water
with 0.1% formic acid and acetonitrile with 0.1% formic acid were purchased from Honeywell
Burdick & Jackson (Muskegon, MI, USA). High grade water was obtained using a Milli-Q
integral water purification system (Billerica, MA, USA). Bovine serum albumin, Dulbecco’s
phosphate buffered saline, formic acid, methanol, Trizma hydrochloride (1M) and tween 20 were
purchased from Sigma-Aldrich (Saint Louis, MO, USA). Glacial acetic acid was obtained from
Macron Fine Chemicals (Center Valley, PA, USA). Sodium chloride solution (5M) and EDTA
solution (0.5M) were obtained from Ambion (Foster City CA, USA). Trypsin Gold was obtained
from Promega (Madison, WI, USA). Biotinylated antibodies to hOPN (MAB222P) were
obtained as a gift from Maine Biotechnology Services (Portland, Maine, USA). The product
information for MAB222P antibodies state that they have affinity towards the ‘DSVVYG’
amino acid sequence of hOPN.

Immuno-capture (IC) buffer was prepared in-house and was

comprised of 0.1/5.0/3.0/0.2/91.7/0.1 (v//v/v/v/w) Tween 20/ Trizma HCl (1M)/ NaCl
(5M)/EDTA (0.5M)/water/ bovine serum albumin. IC wash buffer was prepared in-house and
was comprised of 5.0/3.0/0.2/91.8/0.1 (v/v/v/v) Trizma HCl (1M)/ NaCl (5M)/ EDTA (0.5M)/
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water, respectively. Digestion solution, containing of 500 ng/100 µL of trypsin gold, 0.05 pg/100
µL of SIL-IS peptide II in 50 mM ammonium bicarbonate buffer, was freshly prepared prior to
digestion for validation studies.
6.2.2 Instrumentation
The MFLC-MS/MS system consisted of a Waters NanoAcquity UPLC coupled to at Waters TQS mass spectrometer fitted with a prototype ion key/MS™ separation device. The separation
device consisted of a compact cartridge with an in-built capillary column having an internal
diameter of 150 µm and packed with 1.7 µm particles. HPLC grade water with 0.1% formic acid
and acetonitrile with 0.1% formic acid were used as mobile phase A1 and B1, respectively. The
LC system was operated in the trap mode using a single pump system. A Symmetry C18 Guard
Column, 300 µm x 50 mm from Waters (Milford, USA) was used as the trap column. Trapping
was carried out for 2 minutes at a flow rate of 20 µL/min using 99.5% mobile phase A1.
Analytical separation was performed on a Waters BEH 130 C18 iKey™ Separation Device
(100 mm x 150 μm I.D., 1.7 μm). Gradient conditions were as follows: 0.0–0.5 min, isocratic 5%
B1; 0.5 –3.0 min, linear from 5% to 20% B; 3.0 –5 min, linear from 20% to 30% B; 5.0 –7.0
min, linear from 30% to 95% B; 7.0 –8.4 min, isocratic 95% B; 8.4 –8.5 min, linear from 95% to
5%; 8.4 –8.5 min, isocratic 5% B. The total running time was 9 min and the injection volume
was 20 µL in the full loop mode. Initial flow rate from 0.0 to 0.5 min was kept at 0.5 μL/min to
avoid high back pressure during switch over from trapping to analysis mode. From 0.5 to 8.5
minutes, the chromatographic separation was carried out at a flow rate of 2.5 μL/min. The flow
rate was changed to 1.0 μL/min after 8.5 min. The cone voltage and collision energy were
optimized for each compound using automatic tuning (Intellistart system) in the TQ-S.
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Table 6-1 : Sumamry of LC-MS/MS Paramters
Selected Reaction

Peptide Sequence

Retention

Monitioring (SRM)

Cone

Collision

time

Transitions

Voltage

Energy

(mins)

(Parent ion →

(V)

(V)

Fragment ion)

5.0

m/z 483.6-508.5

15

16

GDSVV*YGLR

5.0

m/z 486.0-508.5

19

14

GDSVVYGLR*

5.0

m/z 488.6-518.4

19

14

TYDGRGDSV*VYGLRSKSKKF

4.6

m/z 568.6-669.4

37

16

GDSVVYGLR

*Stable Isotope labeled amino acid
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The parameters for each compound are listed in Table 6-1. The capillary voltage was 3.6 kV, the
source temperature was 100 °C, the source offset was 60 V, and the collision gas was argon.
Dwell times for all transitions were 0.044 s.
Table 6-1. Sumamry of LC-MS/MS Paramters
6.2.3 Preparation of Standard Solution
Recombinant hOPN standard was reconstituted in dulbecco’s phosphate buffered saline to
prepare a stock solution of 100 µg/ml. Osteopontin calibration standard solutions of varying
concentrations ranging from 25-1000 ng/ml were obtained by spiking hOPN stock solution in IC
buffer.
6.2.4 Sample Preparation Procedure
Commercially available monoclonal antibodies ‘MAB 222P’, which were specific to hOPN and
which had affinities for a specific site on the signature peptide (‘DSVVYG’), were used for
immunoaffinity isolation. Biotinylated anti-hOPN monoclonal antibodies were immobilized on
high capacity streptavidin coated 96 well plates (Thermo scientific, USA). 100 µL of the
osteopontin calibration standard solution was added to each well along with a 50 µL aliqout of IS
peptide I solution. Immunocapture was carried out at room temperature for 4 hours using a
constant vortex of 450 rpm. After 12 hours, the plates were washed 3 times with immunocapture
wash buffer. Digestion was carried out by adding 100 µL of digestion solution containing IS
peptide II to each well and incubating the plates at 37°C in a water bath for 14 hours. Digestion
was terminated by adding 2 µL formic acid to each well. The digested samples were transferred
to a Protein LoBind 96 well plate and analyzed using LC-MS/MS.
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6.2.5 Immunocapture variability evaluation
Biotinylated anti-hOPN monoclonal antibodies (750 ng per well) were immobilized on high
capacity streptavidin coated 96 well plates and used for analysis varying hOPN concentration
(25-600 ng/ml) to evaluate linearity of the method.
Immunocapture variability was forcibly induced by varying the antibody amount i.e. 150, 240,
400, 650, 1050, 1710, 2770 and 4500 ng per well, thus resulting in varying immunocapture
efficiency. A hOPN standard solution of 250 ng/ml was used for all samples in this study. The
samples were processed as per sample preparation procedure and analysed using LC-MS/MS.
The results were expressed as the percent difference from the average response ratio (analyte/IS
peptide I and analyte/IS peptide II) obtained in samples analyzed with the nominal samples.
6.3

RESULTS AND DISCUSSION

Each sample was processed with internal standard addition prior and post immunocapture using
two different IS peptide. Our earlier investigations in chapter 4 showed that under controlled
digestion conditions, the precision is the same when either internal standard is used. This
investigation was conducted under controlled digestion conditions, so we assume that there was
no bias in the digestion variability when either IS peptide is used.
The immunocapture efficiency of the antibody used in this study was 300 fold less than the
antibody used in our previous method. Due to this low absolute recovery, this method was used
only as a proof-of-concept study and was not developed into a fully validated method.
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Figure 6-2: Linearity using modified method
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600

700

The method developed in Chapter 4 was modified, wherein the immunocapture was carried out
with a different antibody whose epitope site’ DSVVYG” was within the selected signature
peptide (GDSVVYGLR). The modified method yielded a linear response with varying
concentration of hOPN as seen from Figure 6-2. This indicates that the system is not saturated
for this hOPN range (25-600 ng/ml) using wells coated with 750 ng of antibody.
A logarithmic increase in analyte peak area was seen with increasing amount of antibody per
well (see Figure 6-3). A deviation from linearity was observed at 1050 ng in the antibody amount
versus analyte area curve for that OPN concentration, indicating saturation of the immunocapture
capacity. Hence, samples analyzed with 1050 ng antibody per well were used as nominal
samples.
A logarithmic increase in IS peptide I (IS added prior to immunocapture) peak area was seen
with an increasing amount of antibody per well (see Figure 6-4). On the other hand, a flat
relationship was seen in the IS peptide I (IS added after immunocapture) peak area was seen with
an increasing amount of antibody per well (see Figure 6-5).
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Figure 6-3: Plot of Analyte peak area versusamount of immunocapture antibody.
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Figure 6-4: Internal standard peptide I (added prior to immunocapture) peak area with a
varying amount of immunocapture antibody.
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Figure 6-5: Internal standard peptide II (added after immunocapture) peak area with a
varying amount of immunocapture antibody
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Figure 6-6: Evaluation of internal standard peptide addition in the immunocapture variability
study
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The comparison of impact of IS addition was before and after immunocapture was done by
evaluating trend of the percent difference from the average response ratio (analyte/IS peptide I
and analyte/IS peptide II) obtained in samples analyzed with the nominal samples. From Figure
6-6, it can be observed that the addition of an extended SIL-peptide IS before immunocapture
compensated for immunocapture. This is shown as the flat trend (variability ranging from 37.5% to 20.3%), as compared to the logarithmically increasing trend (variability ranging from 80.9 % to 77.0 %) when IS was added post immunocapture.
6.4

CONCLUSIONS

This study demonstrates that an extended SIL-IS peptide can be used as an internal standard to
compensate for immunocapture variability during quantification of hOPN by LC-MS/MS.
Extended peptides may be considered as potential internal standards to account for sample
processing variability (immunocapture and digestion) during protein quantification using
immunoaffinity coupled LC-MS/MS. Use of extended SIL-peptides provides a cost effective
internal standardization strategy as an alternate to the use of SIL-proteins. This internal
standardization strategy could be used for quantification of low abundance biomarker proteins
which require immunocapture purification, but do not have commercially available SIL-IS
proteins.
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CHAPTER 7

7

OVERALL CONCLUSIONS

Biomarker quantification plays an important role in clinical disease diagnosis, patient
stratification, therapy selection and therapeutic monitoring (Fleming, et al. 2012, Goodsaid, et al.
2007, Pletcher, et al. 2011). In addition, biomarkers are increasingly being used by the
pharmaceutical industry as surrogate end point markers during drug development to have shorter
clinical trials (Kola, et al. 2004, Lee, et al. 2009). Proteins are the functional biomolecules in
biologically processes. Proteins found in biological fluids such as blood, urine, saliva and milk
are preferred as biomarker molecules, primarily due to the ease of sampling (Dhingra, et al.
2005, Rogers, et al. 2008). Protein biomarker application can involve measurement of the
amount of protein or of the protein activity. Currently, protein biomarker quantification is
dominated by immunoassays. Over the last few decades, immunoassays platforms have
improved from the use of radioimmunoassay to enzyme linked immunosorbent assays (ELISA)
(Hoofnagle, et al. 2009). Immunoassays provided a high sensitivity, high throughput and cost
effectiveness platform to quantify biomarkers. However, immunoassays suffer from selectivity
issues leading to method inaccuracies. Method inaccuracy arising from lack of selectivity can
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lead to biased results, in turn affecting clinical decisions (Hoofnagle, et al. 2009). This led us and
others to evaluate alternative methods for quantification of biomarker protein molecules. This
dissertation focused on developing and validating mass spectrometry based methods for
quantification of protein biomarkers.
Liquid chromatography coupled to mass spectrometry has been the small molecule gold standard
of quantitative analysis for quantification of small molecules for many years now. Over the last
decade, mass spectrometry is increasingly being evaluated as an alternative to immunoassays for
protein biomarker applications (Makawita, et al. 2010, Ramanathan, et al. 2011, Rauh 2012). In
the first chapter, strategies for quantitative analysis of protein biomarker molecules using liquid
chromatography tandem mass spectrometry were discussed. Currently, the most widely used
protein quantification strategy using LC-MS/MS involves the formation of unique peptides upon
enzymatic digestion of the analyte protein (Berna, et al. 2009, Keshishian, et al. 2009, Makawita,
et al. 2010, Rauh 2012, Wang, et al. 2009). These unique peptides, also known as signature
peptides, are then analyzed as surrogate analytes using LC-MS/MS. Method development begins
with in-silico digestion studies of the analyte protein, to identify potential signature peptides and
their mass spectrometric transitions. Enzymatic digestions are then carried out preferably using
recombinant analyte protein and the digests are screened for the presence of the signature
peptides identified during in-silico studies. In the final optimization studies, the signature peptide
that is most selective and has the highest signal intensity is chosen and used as the surrogate
analyte for the protein.
If the biomarker proteins are quantified from complex biological matrices, it is essential that
there is a purification step to isolate the analyte protein or the signature peptide from unwanted
matrix components (Berna, et al. 2009, Keshishian, et al. 2009, Makawita, et al. 2010, Rauh
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2012, Wang, et al. 2009). Biomarker protein concentrations and their physicochemical properties
are main considerations while choosing an appropriate purification strategy. An immuno-based
purification is usually required if the biomarker protein is found in low nanogram levels.
Sometimes a ‘double clean-up’ involving a protein purification step followed by a peptide
purification step is used to achieve cleaner samples and lower detection limits. (Ahn, et al. 2009,
Kushnir, et al. 2013, Neubert, et al. 2013).
Internal standard (IS) selection is an essential method development step for mass spectrometry
based quantitative analysis (Bronsema, et al. 2012, Brun, et al. 2007, Pailleux, et al. 2012, van
den Broek, et al. 2013a). Though stable isotope labeled SIL-proteins are considered ideal internal
standards during protein quantification by LC-MS/MS, SIL-peptides are used for internal
standardization as they are more readily available and have lower cost. However, SIL-peptides
lack the ability to compensate for variability arising from sample processing steps such as protein
purification and enzymatic digestion (Bronsema, et al. 2012, Brun, et al. 2007, Pailleux, et al.
2012, van den Broek, et al. 2013a). Extended SIL-peptides, i.e. SIL-peptides having additional
amino acid residues flanking on either side, can be used as alternatives to SIL-peptides to
account for digestion variability (Bronsema, et al. 2012, Brun, et al. 2007, Pailleux, et al. 2012,
van den Broek, et al. 2013a). In chapter 4, we have demonstrated the ability of an extended SILIS peptide to account for digestion variability. In addition, we have demonstrated that an
extended SIL-IS peptide can compensate for immunocapture variability when the epitope lies
within the region of the signature peptide.
A ‘fit-for-purpose’ method validation is traditionally used for biomarker assays i.e. the method
validation should be evaluated based on its intended purpose. (Bower, et al. 2014, Lee 2009,
Lee, et al. 2006, Stevenson, et al. 2013). Selectivity of the mass spectrometry based biomarker
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assay is ensured by choosing a unique signature peptide and appropriate mass transitions.
Additionally, selectivity can be incorporated in the method through selective isolations such as
protein and peptide immunocapture. Accuracy and precision of the method within an analytical
batch and between batches is evaluated during validation. As biomarkers are endogenous
molecules, calibration curve standards and quality control samples are prepared by spiking
protein reference standards into pooled matrix samples which have low endogenous levels of the
biomarker (Lee, et al. 2009). Alternatively, a surrogate matrix such as analyte stripped matrix or
buffer matrix can be used. A parallelism experiment in which comparison of the sensitivity in the
sample matrix and the surrogate matrix can be used to demonstrate that there are no matrix
differences between the sample matrix and surrogate matrix (Lee, et al. 2009). In addition,
storage stability, in-process stability and post preparative stability is also established during
validation. Method validation ensures that the developed biomarker assay is selective, accurate,
precise and reproducible. This builds greater confidence in the biomarker based decisions in
clinical settings.
In chapter 3, a LC-MS/MS method was developed and validated for measurement of the activity
of the biomarker protein thymidine kinase 1 (TK1) in serum. TK1 is an enzyme involved in
DNA synthesis whose activity in serum is indicative of tumor proliferation and the severity of
blood malignancies (Topolcan, et al. 2008). TK1 activity was measured by monitoring the
conversion of 3’-deoxy-3’-fluorothymidine (FLT), a specific exogenous substrate for TK1, to 3’deoxy-3’-fluorothymidine monophosphate (FLT-MP) (Faria, et al. 2012). Protein precipitation
and on-line SPE was used for analyte isolation prior to LC-MS/MS analysis. The amount of
FLT-MP generated was quantified using LC-MS/MS. The method was linear over the range of
0.5-500 ng/mL for FLT and 2.5-2000 ng/mL for FLT-MP with a mean correlation coefficient of
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0.9964 and 0.9935 for FLT and FLT-MP, respectively. The lower limit of quantification was 0.5
ng/mL for FLT and 2.5 ng/ml for FLT-MP. Intra-assay accuracy and inter-assay accuracy was
within ±12 % for both FLT and FLT-MP. Intra-assay precision was 2.8% to 7.7% for FLT and
3.3% to 5.8% for FLT-MP. Inter-assay precision was 4.6% to 14.9% for FLT and 4.9% to 14.6%
for FLT-MP. Typically, an activity assay is more sensitive to formation of product in comparison
the consumption of the substrate; hence serum TK1 activity was assessed by the formation of
FLT-MP. Serum TK1 activity was measured in serum from hepatocellular carcinoma (HCC)
patients and age-matched controls under standardized conditions. A sub-population of the HCC
patient samples showed an almost 20-fold enhanced TK1 activity compared to the controls. This
method provided a robust alternative to radiometric and immunochemical assays for rapid and
selective determination of serum TK1 activity during oncological screening and monitoring.
In chapter 4, a microflow LC-MS/MS method was developed and validated for measurement of
the biomarker protein human osteopontin from plasma using a biologically relevant signature
peptide. Human osteopontin (hOPN) is a secreted cell signaling protein which is implicated in
the pathogenesis of a variety of disease states, including cardiovascular disorders, cancer, and
several chronic inflammatory diseases (Lund, et al. 2009, Rodrigues, et al. 2007, Waller, et al.
2010). The primary integrin binding site on hOPN is
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RGDSVVYGLR. This region is also a

site known to undergo proteolytic cleavage and is devoid of any post-translational
phosphorylation. The signature peptide’ (GDSVVYGLR) was chosen from this biologically
active region of hOPN. The use of a biologically relevant signature peptide ensures that the
captured hOPN is biologically active. Immunocapture, using hOPN specific antibodies, was
used to isolate hOPN from the plasma matrix prior to tryptic digestion. Online sample
enrichment was performed using column trapping prior to chromatographic separation. Initial
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method development was carried out using a conventional flow liquid chromatographic (LC)
system coupled to an AB Sciex API 4000 Qtrap. The method was transferred to a capillary
microflow Waters ionkey/MS system in order to achieve the detection limits needed for normal
endogenous concentrations of osteopontin. Immunocapture buffer was used as a surrogate matrix
for validation studies. Samples were diluted prior to analysis to eliminate matrix effects. The
method was validated over a range of 25-600 ng/mL. The performance of the method was found
to be compliant with the USFDA validation guidance (Center for Drug Evaluation and Research
(U.S.), et al. 2001).
During method development, the signature peptide was observed to undergo an unexpected
chymotryptic-like cleavage leading to its degradation. An important objective of this chapter was
to evaluate the ability of the stable isotope labeled (SIL) peptide GDSVVYGLR* and an
extended SIL peptide TYDGRGDSVV*YGLRSKSKKF’ as internal standards (IS) to account
for variability and instability of the signature peptide during digestion. Inherent digestion
variability was not significantly different with either peptide IS. However, when the trypsin
activity was varied, the extended SIL peptide was found to be better internal standard to account
for digestion variability. In the digestion variability studies, the use of extended SIL peptide as
internal standard limited the total variability within ±30%. Alternatively, when SIL peptide was
used as internal standard the variability ranged from -67.4% to 50.6 %.
The applicability of the method for measuring plasma OPN levels was demonstrated by analysis
of samples obtained from breast cancer patients and healthy individuals. The method range
covered both healthy and diseased population plasma OPN concentrations. The plasma OPN
concentrations in healthy individuals ranged from 38-85 ng/mL with a mean concentration of
55.4±15.3 ng/mL. A 1.5-12 fold increase in OPN concentrations, ranging from 85-637 ng/mL,
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was seen in breast cancer patient samples. Human osteopontin undergoes post-translational
proteolytic cleavage which can interfere in its quantification in ligand binding assays. The use of
a biologically relevant signature peptide ensures that the captured hOPN is biologically active.
Thus, this method is proposed as an alternative to ELISA and for measuring plasma OPN
concentrations for biomarker applications.
In chapter 5, prelimary studies were conducted to develop a cell based system to evaluate
tobacco products for cardiovascular risk based on the LC-MS/MS measurement of secreted
osteopontin and MMP-3 cleaved osteopontin fragments. Our first objective was to develop a
LC-MS/MS to quantify full hOPN and the MMP-3 cleaved hOPN fragments from cell media.
From our in-silico studies, we predicted that tryptic digestion of hOPN and its MMP-3 cleaved
N-terminal hOPN fragment would yield two different signature peptides i.e. ‘GDSVVYGLR’
and ‘GDSVVYG’, respectively. However, in our preliminary LC-MS/MS evaluation of full
hOPN tryptic digests, we saw that tryptic digestion resulted in the production of only a small
amounts of the ‘GDSVVYG’ peptide, thus negating our ability to quantify the MMP-3 Nterminal hOPN cleaved fragments using LC-MS/MS. Our second objective was to develop an in
vitro method for evaluating the cardiovascular risk potential of tobacco products by measuring
secreted hOPN levels from tobacco extract exposed endothelial cells. EA.hy926 vascular
endothelial cells were exposed to cigarette smoke extract and its supernatant was evaluated for
secreted osteopontin levels along with nicotine and solvent controls, using a modified LCMS/MS method developed in chapter 4. However, it was observed that the secreted osteopontin
concentrations in the supernatant of cell culture studies were below detection limits. Since the
preliminary results did not indicate that this research objective could be addressed with the
proposed system, this study was terminated.
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In chapter 6, in a proof-of-concept study, we evaluated the ability of an SIL-peptide IS peptide to
compensate for immunocapture variability during quantification of human osteopontin (hOPN)
by immunoaffinity coupled LC-MS/MS. For this study, we modified the LC-MS/MS method to
quantify hOPN with a hOPN specific antibody that had an epitope present on the SIL-IS peptide.
Immunocapture variability was induced by varying the antibody amount per well from 150-4500
ng and analysis was carried out with internal standards added before and after the
immunocapture step. The immunocapture variability ranged from -80.9 % to 77.0 % when the IS
was added after immunocapture and from -37.5% to 20.3% when the IS was added before
immunocapture. The lower variability demonstrates the ability of the SIL-IS peptide to
compensate for variation during immunocapture. The immunocapture efficiency was
significantly lower than that of the original method. The low immunocapture efficiency will limit
the detectability of the method for its biomarker application. Hence, this method was not
validated.
With increase in the biomarker applications in drug development and clinical settings, there is a
need for improving analytical technology for biomarker quantification. LC-MS/MS shows great
promise as an analytical tool for quantification of protein biomarkers (Makawita, et al. 2010,
Ramanathan, et al. 2011, Rauh 2012). We developed and validated a method to precisely and
accurately measure the activity of serum thymidine kinase 1 using LC-MS/MS. In addition, we
developed and validated a method to precisely and accurately measure human osteopontin from
plasmas using LC-MS/MS. The method focused on using a signature peptide from the bioactive
region of the human osteopontin, thus, enabling better reliability of this method for biomarker
applications. In addition, our investigations were focused on internal standard correction for

161

protein quantification by LC-MS/MS, and enhanced our present understanding of internal
standardization for protein quantification. We were able to demonstrate that extended SIL-IS
peptides can effectively compensate for immunocapture and digestion variability during human
osteopontin quantification from plasma by LC-MS/MS. These methods provide an alternative to
immunoassay quantification for evaluation of protein biomarkers in clinical settings. In the
future, technological developments in mass spectrometric instrumentation and sample processing
to achieve lower detection limits coupled with better workflow to achieve more rugged methods
will result in greater acceptance of mass spectrometry based quantification methods by
regulatory authorities and the clinical sciences community.
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